SURVIVAL TIME AND PREDICTORS OF MORTALITY AMONG PATIENTS UNDER MULTI-DRUG RESISTANT TUBERCULOSIS TREATMENT IN GONDAR UNIVERSITY HOSPITAL by ASAMENEW ENDAWEKE WALE
i 
 
SURVIVAL TIME AND PREDICTORS OF MORTALITY AMONG PATIENTS UNDER 
MULTI-DRUG RESISTANT TUBERCULOSIS TREATMENT IN GONDAR 
UNIVERSITY HOSPITAL 
 
 
BY 
 
ASAMENEW ENDAWEKE WALE 
 
THESIS SUBMITTED TO 
THE DEPARTMENT OF  STATISTICS 
COLLEGE OF NATURAL AND COMPUTATIONAL SCIENCES     
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE IN BIOSTATITICS 
 
 
 
UNIVERSITY OF GONDAR, GONDAR, ETHIOPIA 
 
MARCH 2015 
ii 
 
SURVIVAL TIME AND PREDICTORS OF MORTALITY AMONG PATIENTS UNDER 
MULTI-DRUG RESISTANT TUBERCULOSIS TREATMENT IN GONDAR 
UNIVERSITY HOSPITAL 
 
 
 
 
BY 
ASAMENEW ENDAWEKE WALE 
 
 
 
ADVISOR 
SALIE AYALE (PhD) 
 
UNIVERSITY OF GONDAR, GONDAR, ETHIOPIA 
 
 
 
 
 
 
MARCH 2015 
iii 
 
DECLARATION 
 
I, the undersigned, declare that the thesis is my original work, has not been presented for Degrees 
in any other University and all sources of materials used for the thesis have been duly 
acknowledged. 
Declared by: 
                        Name: Asamenew Endaweke Wale 
Signature: ------------------------------- 
                       Date:    ------------------------------- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
APPROVAL SHEET- 1 - 
This is to certify that the thesis entitled “SURVIVAL TIME AND PREDICTORS OF 
MORTALITY AMONG PATIENTS UNDER MULTI-DRUG RESISTANT 
TUBERCULOSIS TREATMENT IN GONDAR UNIVERSITY HOSPITAL”‖,  Submitted  
in  partial fulfillment  of  the  requirements  for  the  degree  of  Master  of  Science  in  Statistics  
with  a specialization  of  Biostatistics  of  the  Graduate  Program  of  the  Department  of  
statistics,  University of Gondar,  and  is  a  record  of  original research  carried  out  by  
Asamenew Endaweke Wale,  I.D.No   5103/05  under  my supervision,  and  no  part  of  the  
thesis  has  been  submitted  for  any  other  degree  or diploma.  
The  assistance  and  the  help  received  during  the  course  of  this  investigation  have  been 
duly  acknowledged.  Therefore,  I  recommend  that  it  may  be  accepted as  fulfilling  the 
thesis requirements.  
 
 
 
 
 
 
____________________           ________________                                   _______________  
Name of Advisor                          Signature                                                           Date  
 
 
 
 
 
v 
 
APPROVAL SHEET -2  
We, the undersigned, members of the Board of Examiners of the final open defense by 
Asamenew Endaweke Wale  have read and evaluated his thesis entitled “SURVIVAL TIME 
AND PREDICTORS OF MORTALITY AMONG PATIENTS UNDER MULTI-DRUG 
RESISTANT TUBERCULOSIS TREATMENT IN GONDAR UNIVERSITY 
HOSPITAL:A CASE OF STUDY GONDAR UNIVERSITY HOSPITAL”, and examined the 
candidate. This is therefore to certify that the thesis has been accepted in partial fulfillment of the 
requirements for the degree of Master of Science in Statistics with specialization of Biostatistics 
Statistics.     
______________________       ___________________           _____________  
Name of Chair Person                       Signature                              Date       
______________________       ____________________         _____________  
Name of Advisor                                 Signature                              Date       
______________________       ____________________          _____________  
Name of Internal Examiner               Signature                              Date       
______________________      ____________________          ______________  
Name of External Examiner              Signature                              Date    
 
 
 
 
 
 
 
vi 
 
Table of Contents 
LIST OF TABLES............................................................................................................................ VIII 
LIST OF FIGURES ............................................................................................................................. IX 
ACKNOWLEDGMENTS ................................................................................................................... XI 
ABSTRACT ....................................................................................................................................... XII 
CHAPTER ONE .................................................................................................................................... 1 
1. INTRODUCTION ............................................................................................................................. 1 
1.1 BACKGROUND OF THE STUDY ......................................................................................................... 1 
1.2 STATEMENT OF THE PROBLEM ........................................................................................................ 5 
1.3 OBJECTIVES OF THE STUDY ............................................................................................................ 5 
1.3.1 General objective .................................................................................................................... 5 
1.3.2 Specific objectives .................................................................................................................. 5 
1.4 SIGNIFICANCE OF THE STUDY ......................................................................................................... 6 
1.5 LIMITATION OF THE STUDY ............................................................................................................ 6 
CHAPTER TWO................................................................................................................................... 7 
2.  LITERATURE REVIEW ................................................................................................................. 7 
2.1 DIAGNOSIS OF MULTI DRUG RESISTANT TUBERCULOSIS .................................................................. 7 
2.2 TREATMENT OF MULTI DRUG RESISTANT TUBERCULOSIS .............................................................. 7 
2.3 PREVENTION AND CONTROL OF MULTIDRUG-RESISTANT TUBERCULOSIS......................................... 8 
2.4. RISK FACTORS ASSOCIATED WITH MDR TB................................................................................. 11 
2.4.1 Socio-demographic factors .................................................................................................... 11 
2.4.2 Clinical factors ...................................................................................................................... 14 
CHAPTER THREE............................................................................................................................. 21 
3. METHODOLOGY .......................................................................................................................... 21 
3.1 INTRODUCTION ............................................................................................................................ 21 
3.2 STUDY DESIGN ............................................................................................................................. 21 
3.3 STUDY AREA AND ITS DESCRIPTION .............................................................................................. 21 
3.4 DATA ........................................................................................................................................... 22 
3.5 DATA COLLECTION PROCEDURES .................................................................................................. 22 
3.6 VARIABLES OF THE STUDY ........................................................................................................... 22 
3.7 SURVIVAL DATA ANALYSIS ......................................................................................................... 24 
3.7.1 Descriptive Methods for Survival Data .................................................................................. 25 
3.7.1.1 Kaplan-Meier Estimator ..................................................................................................... 27 
3.7.1.2. Comparing Survival Distributions ..................................................................................... 28 
3.7.2 Modelling Survival Data ....................................................................................................... 30 
3.7.2.1 The Cox Proportional Hazards Regression Model ............................................................... 31 
3.7.2.2 Fitting the Cox Proportional Hazard Regression Model ...................................................... 33 
3.7.2.3 Variable Selection Procedures ............................................................................................ 36 
3.7.3 Assessment of Model Adequacy ............................................................................................ 38 
vii 
 
3.7.3.1 Overall Goodness of Fit ...................................................................................................... 40 
3.7.3.2 Checking for the Proportional Hazards Assumption ............................................................ 41 
3.7.3.3 Checking for Linearity of Continuous Covariates ............................................................... 42 
3.7.3.4 Extensions of the Proportional Hazards Model ................................................................... 42 
3.7.3.5 Interpretation of the Coefficients of the Final Cox-Regression Model ................................. 44 
3.8 PARAMETRIC SURVIVAL REGRESSION MODELS ............................................................................ 44 
3.8.1. The Exponential Survival Regression Model ........................................................................ 45 
3.8.1.1 Fitting the exponential survival regression model ............................................................... 46 
3.8.2. The Weibull Survival Regression Model .............................................................................. 46 
3.8.2.1 Fitting the Weibull Survival Regression model ................................................................... 47 
3.8.3. Model Selection in Parametric Survival Regression Models.................................................. 48 
CHAPTER FOUR ............................................................................................................................... 49 
4. RESULT AND DISCUSSION ......................................................................................................... 49 
4.1 DESCRIPTIVE SURVIVAL ANALYSIS ............................................................................................... 49 
4.1.1 Socio-Demographic Characteristics ....................................................................................... 49 
4.1.2 Clinical characteristics .......................................................................................................... 50 
4.2 COMPARISON OF KAPLAN MEIER SURVIVAL CURVES ................................................................... 51 
+4.3 COX PROPORTIONAL HAZARD REGRESSION MODEL ................................................................... 56 
4.3.1 Univar ate Cox proportional hazards model ........................................................................... 56 
4.4 MODEL ADEQUACY ...................................................................................................................... 58 
4.4.1 Overall Goodness of Fit ........................................................................................................ 58 
4.4.2 Testing the Proportional Hazards Assumption ....................................................................... 59 
4.5 INTERPRETATION AND DISCUSSION OF THE RESULTS ..................................................................... 60 
4.6. PARAMETRIC REGRESSION MODELLING OF SURVIVAL TIME OF MDR TB PATIENTS .................... 62 
4.6.1. Model Selection for Survival Time of MDR TB Patients ...................................................... 62 
4.6.2 Univariate unadjusted Weibull regression model ................................................................... 64 
4.6.3 Multivariable Analysis Weibull regression model .................................................................. 65 
4.6. 4 Assessment of Adequacy of the Weibull Regression Model .................................................. 66 
4.6.5. Interpretation and Discussion of the Weibull Regression Model ........................................... 66 
CHAPTER FIVE ................................................................................................................................. 70 
5.  CONCLUSION AND RECOMMENDATION .............................................................................. 70 
5.1 CONCLUSION................................................................................................................................ 70 
5.2 RECOMMENDATION ...................................................................................................................... 71 
REFERENCES .................................................................................................................................... 72 
APPENDIX B ...................................................................................................................................... 76 
APPENDIX C ...................................................................................................................................... 82 
APPENDIX D: STATA AND SAS CODES ........................................................................................ 87 
 
viii 
 
 
List of Tables  
Table 3.1: Description of the Independent variables.................................................................. 23 
Table 4.1: Summary of some important socio-demographic characteristics of MDR TB patients 
at Gondar University hospital .................................................................................................... 49 
Table 4.2: Summary of some important clinical characteristics of MDR TB patients at Gondar 
University hospital .................................................................................................................... 51 
Table 4.3: over all mean for survival time of MDR TB patients and their 95%CI & SE. ........... 52 
Table 4.4:  mean duration for survival time of MDR TB patients and their 95%CI & SE by 
different socio-demographic and clinical characteristics based on Kaplan-Meier technique ....... 53 
Table 4.5: Results of log-rank test of equality of survival distribution for the different 
categorical covariates ................................................................................................................ 55 
Table 4.6: the Preliminary Final Model with parameter estimates and hazard ratios of the 
covariates .................................................................................................................................. 58 
Table 4.7: The Likelihood Ratio, Score and Wald tests for overall measures of goodness of fit of 
the preliminary final model in table 5A ..................................................................................... 59 
Table 4.8: Result of test of proportionality assumption for each covariate in the final model .... 60 
Table 4.9: Statistics for model comparison ............................................................................... 63 
Table 4.10.The result of un-adjusted univariate analysis using Weibull regression model ......... 64 
Table 4.11.Summary of parameter estimates of the final multivariate weibull model ................ 65 
Table 4.12 The likelihood ratio and significance of the Weibull regression model .................... 66 
Table 1B Kaplan-Meier estimates of time to death for MDR TB patients .................................. 76 
Table 2B: Results of the univariable proportional hazards Cox regression model...................... 77 
Table 3B: Result of the multivariable proportional hazard regression model containing the 
variables significant in the univariabe proportional hazard model. ............................................. 78 
Table 4B: Result of Wald statistic P-values when possible interactions terms included in reduced 
model one at a time ................................................................................................................... 78 
Table 5B: Result of the Exponential regression model with corresponding AIC and BIC values
 ................................................................................................................................................. 79 
Table 6B: Result of the Weibull regression model with corresponding AIC and BIC values ..... 80 
Table 7B: results of the step wise variable selection of weibull regression analysis. .................. 81 
ix 
 
 
List of Figures 
Figure 4.1: Overall product limit estimate of survival function………………………………...52 
Figure 4.2: The Cox-Snell plot after fitting Exponential regression model…………………….63 
Figure 4.3: The Cox-Snell plot after fitting Weibull regression model…………………………63 
Figures 1C: Plots of Kaplan-Meier survivor functions, for different covariates………………..84 
Figure 2C: Plots of the Scaled Schoenfeld residuals and their lowess smooth obtained from the 
final model for the covariate Therapeutic delay…………………………………………………86 
Figure 3C: Plots of the Scaled Schoenfeld residuals and their lowess smooth obtained from the 
final model for the covariate Number of drugs at initiation………………………………..........87 
Figure 4C: Plots of the Scaled Schoenfeld residuals and their lowess smooth obtained from the 
final model for the covariate Alcohol intake of the patient……………………………………...87 
Figure 5C: Plots of the Scaled Schoenfeld residuals and their lowess smooth obtained from the 
final model for the covariate any clinical complication of the patient of the patient……………87 
Figure 6C: Plots of the Scaled Schoenfeld residuals and their lowess smooth obtained from the 
final model for the covariate HIV co-infection of the patient……………………………….......88 
Figure 7C: Plots of the Scaled Schoenfeld residuals and their lowess smooth obtained from the 
final model for the covariate chronic co-infection of the patient………………………………..88 
 
 
 
 
 
 
 
 
x 
 
         Acronyms 
AFB                 acid-fast bacilli 
AIC                   Akaki Information Criteria 
           AIDS                Acquired Immune Deficiency Syndrome  
         BIC                   Bayesian Information Criteria                
CI                     Confidence Interval 
            NDACA  National Drug Administration and Control Authority 
DOT                directly observed therapy 
DST                drug susceptibility testing 
EFMOH           Ethiopian Federal ministry of health 
GLC                 Green Light Committee 
HIV                  Human Immunodeficiency Virus 
HR                   Hazard Ratio 
INH                isoniazid 
KM                  Kaplan-Meier 
LR                   Likelihood Ratio 
MDR-TB         Multidrug resistant tuberculosis 
MLE                Maximum Likelihood Estimator 
MOH              Ministry Of Health 
RIF                   Rifampicin 
SE                    Standard Error 
SPSS                Statistical Package for Social Science 
TB                    Tuberculosis   
UNITAID        United nation fund to fight AIDS 
US                     united States 
            WHO                World health organization 
            XDR-TB            Extensively drug resistant tuberculosis 
xi 
 
Acknowledgments 
First, and foremost, I thank God for giving me the opportunity to pursue my graduate study in 
the Department of Statistics, University of Gondar. 
I would like to sincerely thank Dr. Salie Ayalew, my advisor, for his guidance and 
encouragement from the beginning to the end of the study. 
 
I would like to thank University of Gondar referral Hospital MDR TB staffs who allowed and 
facilitate all the inputs for data collection. 
 
 I am highly indebted to all my families who were the source of strength towards the successful 
completion of the study.  
I acknowledge with appreciation the help rendered by all my dear friends who encouraged me to 
work hard.  
Lastly, I would like to thank Dire Dawa University for sponsoring me to attend this program in 
general.   
 
 
 
 
 
 
 
 
xii 
 
ABSTRACT 
Multi drug resistant Tuberculosis (MDR TB) is a chronic infection disease that has a major 
health problem over the centuries and it has accounted for more human misery suffering and 
loss of earning and failure of economic and social development than any other disease. The aim 
of this study was to identifying the risk factors associated with time to death among MDR TB 
patients treated under directly observed short course treatment program in Health facilities at 
Gondar University hospital, Ethiopia. The data for this study was obtained by accessing medical 
records of MDR TB patients registered during August 2010 to August 2014and treated in 
Gondar University Hospital. Kaplan-Meier estimation method, Cox proportional hazard 
regression model and parametric regression models were applied.  The Cox proportional hazard 
analysis indicated that therapeutic delay after one month, number of drugs taken only INH and 
RIF, alcohol use and HIV positive co-infected patients are significantly contribute to shorter  
survival time whereas patients without any clinical complication and with no chronic co-
infection were significantly contributed to longer survival time  of MDR TB patients. The result 
from Weibull regression analysis showed that elder MDR TB patients, therapeutic delay after 
one month, MDR TB patients taken only INH and RIF at initiation, patients who took alcohol, 
MDR TB patients with different clinical complication, previously not treated MDR TB patients, 
HIV positive patients and MDR TB patients with different chronic co-infections significantly 
contribute a shorter survival time of MDR TB patients.  The major factors that affect the survival 
of MDR-TB patients are Age, therapeutic delay, number of drugs taken at initiation, alcohol use, 
any clinical complication, MDR category, HIV co-infection and chronic co-infection.  
 
Key Words: MDR TB, Kaplan-Meier, Cox Proportional Hazard, Weibull Regression Model, 
Survival Analysis, Ethiopia 
1 
 
CHAPTER ONE 
1. INTRODUCTION 
1.1 Background of the study 
Multi-drug resistant tuberculosis (MDR-TB) is defined as resistant to at least isoniazid (INH) 
and Rifampicin (RIF), the two most important first line anti-Tb drugs. MDR-TB is a man-made 
problem. When patients stop taking or do not take enough of the right medications, the poor 
quality of anti-tuberculosis drugs supply and due to the poor follow up of the means of 
tuberculosis transmission leads to the emergence and spread of mycobacterium tuberculosis 
strains resistant to multiple drugs which represent a major public health problem in a number of 
countries and an obstacle to effective global TB control (WHO, 2011). 
MDR-TB is a droplet infection and is easily transmitted to immune compromised individuals, 
especially to the HIV infected. Experiences in African countries showed that transmission among 
HIV infected individuals results in MDR-TB micro-epidemics, both non societal and societal. 
Multidrug resistance can be primary or acquired. Primary resistance is defined as resistance in 
patients without a history or other evidence of previous anti-tuberculosis drug treatment. 
Acquired drug resistance occurs in those who have previously received anti-tuberculosis 
treatment for at least one month and in those with treatment failures and relapses. The prevalence 
of primary multidrug resistance is 3% and that of acquired multidrug resistance is 12% in India 
(WHO, 2008). Although drug resistance started appearing in patients with M. tuberculosis 
infection soon after the introduction of effective anti-tuberculosis drugs, multidrug-resistant 
tuberculosis was not a major public health problem until the early 1990s when HIV infection 
became a global epidemic. A history of tuberculosis and previous anti-tuberculosis treatment are 
the most important factors identified in the causation of multidrug-resistant tuberculosis. Factors 
which predispose a patient to development of multidrug-resistant tuberculosis include 
(Yashodhara B. et al, 2010): 
- Incomplete treatment 
- Inadequate treatment 
-  Errors in tuberculosis management, such as use of a single anti-tuberculosis drug 
- Addition of a single drug to a failing regimen  
- Failure to identify pre-existing resistance 
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-  Initiation of an inadequate primary regimen 
- Failure to identify and address no adherence to treatment 
- Noncompliance 
-  Inappropriate isoniazid preventive therapy 
-  Variations in bioavailability of anti-tuberculosis drugs 
MDR-TB cases are classified into two categories. The one who has primary resistance, a newly 
registered episode of TB in a patient who, in response to direct questioning, denies having had 
any prior anti-TB treatment (for less than one month), and in countries where adequate 
documentation is available, for whom there is no evidence of such history and those who have 
acquired resistance, A newly registered episode of TB in a patient who, in response to direct 
questioning admits having been treated for TB for one month or more, or, in countries where 
adequate documentation is available, there is evidence of such history. Chemoprophylaxis should 
not be considered treatment for TB consisting of the majority of cases. Insufficient previous 
treatment is a strong prognostic factor in the development of MDR-TB. Many of the MDR-TB 
patients had been taking anti-TB drugs for a long time, and often irregularly, which resulted in 
treatment failure (Espinal M.  et al, 2001 and Seyed  M. et al, 2005). 
 MDR-TB patients respond poorly to short course chemotherapy and need to be treated 
intensively for up to 24 months with a regimen based on reserve anti-tuberculosis drugs (WHO, 
2003). MDR-TB is an increasing global problem. The extent and burden of MDR-TB varies 
significantly from country to country. Globally, the proportion is higher in patients who had 
previously received anti-tuberculosis (anti-TB) treatment reflecting the failure of programs 
designed to ensure complete cure of patients with tuberculosis ( Baptista I. et al, 2008).  
 
WHO estimates that, 440 000 people had MDR-TB in 2010 and that result a 150 000 deaths from 
MDR-TB worldwide. In 2010, the largest WHO MDR-TB survey reported the highest rates ever 
of MDR-TB, with peaks of up to 28% of new TB cases in some settings of the former Soviet 
Union, including regions sharing borders with the European Union (WHO, 2011). World Health 
Organization estimated that there were about 0.5 million new MDR-TB cases in the world in 
2011. About 60% of these cases occurred in Brazil, China, India, the Russian Federation and 
South Africa alone. Asia bears the burden of the epidemic as almost 50% of MDR-TB cases 
worldwide are estimated to occur in China and India .High prevalence of MDR-TB was also 
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found among new cases in Ecuador, and Israel. Central Europe and Africa, in contrast, reported 
the lowest median levels of drug resistance (WHO, 2013).  
A total of 94 000 TB cases eligible for MDR-TB treatment (84 000 with MDR-TB and 10 000 
with rifampicin resistance detected using Expert MTB/ RIF) were notified in 2012, mostly by 
European countries, India and South Africa. This represented progress compared with 2011, 
when 62 000 MDR-TB cases and 4000 rifampicin resistant TB cases were detected; the largest 
increases between 2011 and 2012 were in India, South Africa and Ukraine (WHO, 2013). 
However, worldwide and in most countries with a high burden of MDR-TB, less than one third 
of the TB patients estimated to have MDR-TB were actually detected in 2012. Just over 77 000 
people with MDR-TB were started on second line treatment in 2012, equivalent to 82% of the 94 
000 newly detected cases that were eligible for such treatment globally. Report and published in 
2004 have MDR-TB rates >2.0% of all combined TB cases in Africa. This finding suggests that 
completing DRSs for all or most countries in the AFRO region is urgently needed and that the 
MDR-TB threat in Africa could be much higher than originally assessed by WHO in its previous 
report in 2004. Drug-resistant strains, along with HIV/AIDS, are causing the biggest challenge to 
efficient management and control of TB. The lower rates of MDR-TB in Africa, when compared 
with rates in Eastern Europe or South America, could be related to the fact that for many years 
Africa was neglected and TB was not treated. Alternatively, later introduction of rifampin in 
drug regimens is often cited as an explanation for these low rates. Meanwhile in Africa, where 
little data is available, an estimated 69 000 cases emerged in 2009, but the vast majority of them 
went un-diagnosed (WHO, 2013 and EFMOH, 2013). 
According to WHO 2008, in Ethiopia, 5825 MDR-TB cases (4964 among newly diagnosed and 
861 among previously treated TB cases) were estimated to have occurred in 2006. According to 
the anti-TB drug resistance survey conducted nationwide in 2005 (EHNRI/EFMOH), among 804 
newly diagnosed TB cases 1.6% were found to be infected with MDR-TB. The rate of MDR TB 
among specimens from 76 previously treated TB cases was 11.8%. The same survey reported 
that, TB with Isoniazid mono-resistance and Rifampicin mono-resistance, among new TB cases, 
was 2% and 1%, respectively. Notified prevalence of mono-resistance to INH and Rifampicin 
among previously treated TB cases was 5.3% and 1.3%, respectively. Based on the prevalence 
rate from the survey and TB case notification in 2007/08 the magnitude of MDR-TB in Ethiopia 
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was estimated to be 997 cases, which includes 651 and 346 MDR-TB cases among newly 
diagnosed and re-treatment cases respectively (EFMOH, 2009). 
The treatment of MDR-TB with second line drugs is long, complex and costly, and has a 
considerable rate of adverse effects. Recent progress has been made globally in improving policy 
environment and advances in TB drug development to embark on trials of MDR-TB treatment to 
identify optimal treatment protocol for drug resistant Tuberculosis. The TB Control Program in 
Ethiopia has not yet started managing MDR-TB cases with efficient second line protocols. No 
second line anti-TB drugs are available in Ethiopia, with the exception of fluoroquinolone, and 
the importation of any drug is as per the regulation of the National Drug Administration and 
Control Authority (DACA). But there are evidences that a small cohort of patients were treated 
in some facilities in Addis Ababa and regions, The Ethiopian Government has identified MDR-
TB as one of priority public health problem and it is committed to initiate comprehensive 
treatment for MDR-TB cases in the country. The EFMOH has also clearly endorsed the 
mechanism of single procurement and controlled use of the second line anti-TB drugs, when they 
are available, after acceptance from the Green Light Committee (GLC) and stands for this unique 
channel. Management of MDR-TB will be an integral component of the NTP and will be 
implemented through the existing health care delivery system (EFMOH, 2013). 
The FMOH has set up a specific group of specialists to provide expert advices on MDR-TB 
issues, and has drafted a Plan of Action for MDR-TB control and care. The MDR-TB Technical 
Working Group was established by the EFMOH and other partners to support MDR-TB 
activities in the country. It was the decision of the EFMOH to develop clinical and program 
management guideline for DR-TB with the technical support of MDR-TB Technical Working 
Group and technical assistance of well renowned international experts in the area, before 
launching case management in public institutions under close supervision and follow up of 
National TB control program. In 2002, MDR-TB in Ethiopia was also reported in about 1.2% of 
new cases and 12% of re- treatment cases. According to WHO 2009 report there are 1.6% MDR-
TB patients among all new TB cases and 12% MDR-TB patients among previously treated TB 
cases in Ethiopia. Of the 27 countries with a high burden of MDR-TB and extensively drug 
resistant TB (XDR-TB), 13 countries with data on treatment outcomes for MDR-TB cases 
reported a success by 25%-82% among patients that started on treatment in 2007 (WHO, 2009).  
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 1.2 Statement of the problem 
World health organization estimates that there were about 450,000 new (incident) MDR-TB 
cases in the world in 2012. Since the treatment of MDR-TB in Gondar university hospital started 
recently, the survival rate and its determinant factors among patients under MDR-TB treatment 
are not described. Randomized controlled trials and other researches are done in moderate 
evidence and methodology for optimizing treatment regimens, accessing the risk factors and 
estimating survival times in MDR-TB patients. In addition treatment of pediatric MDR-TB and 
survival time of MDR-TB patients including treatment duration exists in current condition in 
Gondar university hospital. It is believed that, in resource poor countries like Ethiopia the 
survival of MDR-TB patients under DOTS program depends on a variety of factors, which may 
also vary greatly with socio-demographic, behavioral risk and health factors. So, Identification of 
survival time and risk factors of mortality in MDR-TB cases is essential for proper planning and 
effective implementation of MDR-TB treatment. Therefore it is important to examine the risk 
factors for the survival of MDR-TB patients and clearly identifying the risk factor of mortality of 
MDR-TB patients treated under University of Gondar hospital. The crucial questions that the 
study answers were:  
 What are the major factors that facilitate the death of MDR-TB patients under treatment? 
 What are the survival probabilities of MDR-TB patients at time t? 
 What is the median survival time of MDR- TB patients under the treatment program? 
 Which groups among various levels of factors have high risk of death? 
1.3 Objectives of the study 
1.3.1 General objective   
The general objective of this study is to estimate the survival time and predictors of mortality 
among patients under Multi-Drug Resistant Tuberculosis treatment at Gondar University 
Hospital. 
1.3.2 Specific objectives 
The specific objectives of the study are: 
 Estimating the survival time of MDR-TB patients. 
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 To compare the risk between different exposure groups and associated factors with 
survival time of patients under MDR-TB treatment. 
 To develop a statistical model that predicts the survival of MDR-TB patients in the 
hospital using significant risk factors. 
  1.4 Significance of the study 
Expanding access to MDR-TB therapy is urgently needed, yet poor implementation of such 
therapy can worsen the problem of XDR-TB. Understanding risk factors for poor treatment 
outcomes (death) among MDR-TB patients is necessary to improve treatment outcomes. 
Therefore, examining a cohort who received a standardized second-line therapy and management 
of MDR-TB to determine the overall survival time and its determinant factors has a great 
importance. In addition understanding risk factors for death among MDR-TB patients is 
necessary to improve treatment outcomes. Since the treatment of MDR-TB in Ethiopia started 
recently, the survival time and its determinant factors among patients under MDR-TB treatment 
are not well described. Therefore, identification of survival time and risk factors of mortality in 
MDR-TB cases is essential for proper planning and effective implementation of MDR-TB 
treatment. Estimating the survival time and identifying predictors of mortality for MDR-TB 
patients is also important to inform public health authorities, policy makers and stakeholders 
about risk factors for the survival time and mortality of MDR-TB patients. The findings would 
help to bring MDR-TB problem to the agenda of public health policy makers, researchers, and 
the public at large, so that appropriate treatment and control strategies are implemented along 
with a population wide surveillance intervention. 
1.5 Limitation of the Study 
 The data were extracted from medical records of those who already visited and registered 
at the respective health facilities; it may be subjected to bias.  
 The study was restricted to adults, and results might not be applicable to infants and 
children.  
 The study is based on only the set of data for which complete information on survival 
times are available because of missing values.  
 Underestimation of mortality due to lost to follow up patients included in the study. In 
addition to this all deaths are assumed to be caused by MDR-TB. 
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CHAPTER TWO 
2.  LITERATURE REVIEW 
2.1 Diagnosis of multi drug resistant tuberculosis 
The first step in diagnosing drug-resistant TB is to recognize that the patient is at risk and to 
expedite the laboratory diagnosis of TB. The diagnosis of tuberculosis (TB) frequently requires a 
high index of suspicion, especially in low-prevalence areas. Once TB is considered, sputum or 
other specimens for acid-fast bacilli (AFB) smear, growth detection, and susceptibility testing are 
collected. The possibility of drug-resistant TB should be considered simultaneously with 
specimen collection and selection of the initial treatment regimen. Failure to consider the 
possibility of drug-resistant TB until drug susceptibility tests return weeks to months later can 
result in unnecessarily inadequate drug regimens. 
While a number of diagnostic tests exist, TB is typically diagnosed in many settings throughout 
the world based on clinical symptoms and on a sputum smear test in which the sputum smear is 
stained and viewed under a microscope. The results are often confirmed by culturing the sputum 
to check for growth of the TB bacteria. However, the diagnosis of MDR-TB is more difficult as 
it requires special laboratory diagnostic capacity for drug-susceptibility testing, but many 
countries, especially in low-income settings, have little or no diagnostic capacity for MDR-TB. 
Globally, only 5% of new cases and 9% of previously treated cases received testing for drug-
resistance. Detection of TB without testing for drug-resistance can lead to poor treatment 
outcomes, additional and unnecessary suffering and costs for patients, as well as further spread 
of drug resistant strains. 
 2.2 Treatment of Multi Drug Resistant Tuberculosis  
In order to bring new treatments to deal in increased infrastructure, new trial designs, increased 
clinical trial capacity, clear regulatory guidelines, and biomarkers for prediction of long-term 
outcome and ultimately novel drug combinations are needed.  In the last 40 years there has been 
little advancement in TB treatment, which has contributed to a rise in multidrug-resistance. 
There are currently several drugs available for the treatment of TB. However, these treatments 
are older and a significant amount of drug resistance has developed over the years. When first-
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line drugs fail, second-line drugs are used to treat MDR-TB. They must be taken for up to two 
years in order to cure the infection, placing patients at an increased risk for side-effects and drug 
interactions. Failure to comply with this treatment regimen can lead to XDR-TB, which occurs 
when patients become resistant to at least one of the injectable second-line anti-TB medicines, 
amikacin, kanamycin and/or capreomycin, and to a fluoroquinolone. In countries with high 
proportions of TB drug resistance and those with a large population of TB and HIV/AIDS co-
infection, developing rapid detection methods and improving the management of patients with 
drug-resistant TB is an urgent priority. 
Treatment of patients with multidrug-resistant TB is one of the bases of results of drug 
susceptibility testing (DST) obtained before the treatment initiation. Each dose is given as 
directly observed therapy (DOT) throughout the treatment. The duration of MDR-TB treatment 
is 18 to 24 months. The intensive phase being a minimum of six months and the continuation 
phase 12 to 18 months. Patients with MDR-TB confirmation but not with full DST result are 
treated with Ethambutol, Pyrazinamid (Z), Kanamycin (Amicacin), Levofloxain (Lfx), 
Ethionamid (Eto) and Cycloserin (Cs). MDR-TB patients susceptible to both Kanamycin and 
Quinolons are treated as in the first case. MDR-TB patients susceptible to Kanamycin but 
resistant to Quinolons are treated with Ethambutol, Pyrazinamid (Z), Kanamycin (Amicacin), 
Moxifloxacin, Ethionamid, Cycloserin and Para Amino Salicylic Acid (PAS) 
(WHO/HTM/TB/2008.402) Geneva.   
2.3 Prevention and control of multidrug-resistant tuberculosis 
Weak national health systems impede basic control and facilitate re-appearance and spread of 
drug-resistant tuberculosis. Effective control requires appropriate national policies, trained and 
motivated staff, and quality-assured laboratory- and medicine-supply systems supported by an 
adequately funded tuberculosis program. All health-care facilities used by patients with 
symptoms of tuberculosis must be engaged with general and specialized hospitals, academic 
institutions and the array of diverse private-care providers need to be involved as a priority. A 
network of patient-friendly health clinics and staff is essential to ensure that treatment is 
supervised in a supportive manner and is quality-assured, free of cost, and easy to access. If 
patients discontinue their treatment, there must be mechanisms to trace them and re-establish 
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treatment. Moreover, informed, motivated and resourced communities can contribute to case 
finding and adherence support especially in resource-poor settings.  
Presently, less than 5% of the estimated cases of multidrug-resistant tuberculosis are being 
diagnosed (WHO, 2009). Many countries, especially in Africa, lack laboratory capacity to 
culture Mycobacterium tuberculosis and do drug-susceptibility tests. Laboratory capacity, 
neglected for a long time, needs rapid expansion under international norms and standards, as part 
of the strengthening of a broader national public health laboratory system; the Global Laboratory 
Initiative of WHO and partners is helping to enhance coordination of the response. New 
technologies that can accelerate the diagnosis of drug-resistant tuberculosis are available, but not 
yet widely implemented, the main obstacle being lack of an adequate, safe laboratory 
infrastructure and appropriately trained staff. National programs need policies on where and how 
to treat drug-resistant tuberculosis cases. In some countries, patients are admitted to hospital for 
long periods of time, which is labor-intensive and costly, raises important ethical and social 
issues, and increases the risk of nosocomial transmission if infection control is weak. New 
models of care enabling safe and effective treatment supplemented by community-based support 
have proven to be feasible and effective in low-resource settings. To expand treatment services 
effectively and rapidly, countries will need centers of excellence to ensure adequate capacity 
building of health-care providers for tuberculosis management. A large proportion of 
tuberculosis patients are diagnosed and treated in the private sector in many countries and the 
quality of management is uneven: the patients detected are not notified and their treatment 
outcomes are unknown. Modes of collaboration with the private sector for care and control 
including management of multidrug-resistant tuberculosis, in which patients do not have to pay 
for costs of care, have proved effective in resource-poor settings and are necessary for rapid 
expansion of multidrug-resistant tuberculosis management. Health ministries should involve the 
private-care sector in ensuring provision of quality treatment through public–private mix 
approaches linked with the national tuberculosis program. 
Although some individuals who have not had previous TB treatment are infected by MDR-TB, 
this is not the case for most patients. Many new cases of MDR-TB are created each year by a 
combination of physician error and poor patient compliance with treatment, which turn fully 
susceptible organisms, or those with less complex resistance patterns, into MDR-TB. Professor 
Michael Iseman, the US „guru‟ of MDR-TB, has shown that two to four errors are needed to turn 
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a fully susceptible organism into a case of MDR-TB (Iseman MD (1993). Accordingly, there 
were Ten Commandments for physicians: the first is never to add a single drug to a failing 
regimen, and the other nine are for the physician to repeat the first commandment nine times to 
make sure that the message is understood. Support and funding of national TB programs, in 
which treatment is given as directly observed therapy (DOT), is essential for all persons with TB 
if at all possible. Physicians should always use evidence-based treatment guidelines and drugs of 
proven bio-availability. The WHO recommends a 6 month initial treatment regimen of 
rifampicin, isoniazid, pyrazinamide and ethambutol for 2 months, followed by rifampicin and 
isoniazid for 4 months (2RHZE–4RH). If the patient fails treatment (positive cultures or sputum 
smears in months 5 or 6 of treatment) or relapses, an 8 month retreatment regimen is 
recommended. This consists of streptomycin, rifampicin, isoniazid, pyrazinamide and 
ethambutol for 2 months, followed by rifampicin, isoniazid, pyrazinamide and ethambutol for 1 
month, followed by rifampicin, isoniazid and ethambutol for 5 months (2SRHZE–1RHZE–
5HRE), (WHO,1996). 
People living with HIV are more susceptible to developing tuberculosis, including drug-resistant 
tuberculosis. Also, HIV infection greatly increases the fatality rate among multidrug- and 
extensively drug-resistant tuberculosis. Improved and strengthened collaboration between 
tuberculosis and HIV programs is required to prevent rapid transmission of drug-resistant 
tuberculosis and resulting high mortality among communities heavily affected by HIV. To this 
end, WHO recommended that collaborative tuberculosis/HIV activities should be expanded 
(Documents WHO/HTM/TB/2004.330). Quality-assured medicines are essential for successful 
treatment of tuberculosis. Manufacturing processes must meet international standards and the 
quality of the finished product must be assured. WHO standards for quality medicines are not 
always observed. Quality-assured fixed-dose combinations, developed as a tool to prevent the 
emergence of resistance, are not widely used. Inadequate supply of quality-assured second-line 
medicines has been a major issue. Since 2000, the Green Light Committee, established by WHO 
and partners, has provided access to medicines that are quality assured to WHO standards, and 
concessional priced, for projects worldwide that apply WHO guidelines. Concerted action on the 
part of governments, drug-regulatory authorities, the pharmaceutical industry, and WHO is 
required to ensure that adequate and uninterrupted supply of quality-assured anti-tuberculosis 
medicines are available and accessible to all those in need. Combined with a cost per patient 
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treated that is usually in the range US$ 3000–10 000 the total cost of treating 1.5 million cases 
amounts to US$ 11 500 million over seven years, rising from US$ 500 million in 2009 to US$ 
3100 million in 2015; the latter figure is 43 times the funding available in 2009 and 53% of the 
total funding required for tuberculosis control. Most funding is required in the European Region 
(US $7800 million), followed by Asia (US$ 2800 million). In order to mobilize the required 
funding for improved management of multidrug- and extensively drug-resistant tuberculosis, 
preparation of country-specific budgets as part of national strategic plans is the first step that 
needs to be taken. World Health Organization has prepared a planning and budgeting tool for this 
purpose. Domestic resources need to be accessed especially in middle-income countries. If 
sufficient domestic funding cannot be mobilized, countries should make full use of resources 
available from the Global Fund to Fight AIDS, Tuberculosis and Malaria, the International Drug 
Purchase Facility (UNITAID), and other donor agencies and funding mechanisms. 
2.4. Risk factors associated with MDR TB. 
2.4.1 Socio-demographic factors   
Sex 
Doo J. et al. (2010) conducted a retrospective study on treatment outcome and mortality among 
patients with multi-drug resistant tuberculosis in tuberculosis hospitals of the public sectors of 
Korea. The study aims to evaluate treatment outcomes, mortality and predictors of both in MDR-
TB patients at the three TB hospitals in the public sector of Korea. The study covered a total of 
202 (135 males and 67 females) MDR TB confirmed patients and obtained that male sex is an 
independent predictors of poor outcome.   
Selamawit H. et al. (2013) studied Determinants of multidrug-resistant tuberculosis in patients 
who underwent first-line treatment in Addis Ababa: a case control study. The study was 
conducted at St. Peter Hospital and five health centers in Addis Ababa having equal number of 
cases and controls and aims to assess factors that determine the occurrence MDR-TB among 
patients who had taken first line anti-TB treatment in Addis Ababa City. The study covered a 
total of 134 cases and from this 81 (60.5%) of the MDR-TB cases were males and the rest 53 
(39.5%) were females. In addition, the study also found that being male was a risk factor for 
MDR-TB development. A study in Nigeria, Daniel O. et al. (2006) Default from tuberculosis 
treatment programme in Sagamu, Nigeria, also showed that being male was a risk factor for 
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defaulting from anti-TB medication. Similarly, this study showed that among MDR-TB cases 
who were defaulters in their first-line TB treatment, 62.5% were males. The association between 
being male and having MDR-TB could be due to the fact that males have a higher tendency not 
to adhere to anti-TB treatment than females, thus increasing their risk of developing MDR-TB. 
Age 
Alena S. et al. (2013) conducted a national survey on Multidrug-resistant tuberculosis in Belarus: 
the size of the problem and associated risk factors. The study covered a total of 1344 cases of 
MDR TB including 934 new and 410 previously treated cases. The objective of the study was to 
assess the problem of multidrug-resistant tuberculosis (MDR-TB) throughout Belarus and 
investigate the associated risk factors by using univariate and multivariate logistic regression 
analysis. They found that an age of < 35 years was found to be an independent positive risk 
factor for MDR-TB. 
Getachew et al. (2013) conducted a retrospective analysis on survival and predictors of mortality 
among patients under multi-drug resistant tuberculosis treatment in Ethiopia: St. Peter‟s 
specialized tuberculosis hospital, Ethiopia. The objective of the study was to assess survival and 
predictors of mortality among patients under MDR-TB treatment in Ethiopia: St Peter‟s 
specialized TB Hospital, Addis Ababa, Ethiopia. The study covered a total of 188 patients and 
analyzed using Cox proportional hazards model. The study was mainly conducted to assess the 
socio-demographic and clinical factors for the development of MDR-TB. They found that the 
majority of MDR-TB patients were younger aged less than 35 years (81.38 %) with median age 
of 27 years. In addition to that they also revealed that survival of patients under MDR-TB 
treatment was not associated with age. 
Ahmed M. et al.  (2010)  conducted a review on risk factors for multi-drug resistant tuberculosis. 
The main aim of the review was to determine the risk factors associated with multi-drugs 
resistant TB (MDR-TB). The review was critically assessing the risk factors that are associated 
with multi drug resistant tuberculosis. The review suggested that age has been found to be 
independently associated with drug resistance and there was significantly higher proportion of 
MDR-TB among the age group of 45-64 years. It also found that MDR-TB was more likely in 
patients under 65 years, but the association was weak and more heterogeneous in patients under 
45years.  
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Drobniewski, F. et al. (1997) conducted a retrospective study on national study of clinical and 
laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in 
the UK. The study covered a total 90 MDR-TB patients for the aims of to describe the clinical, 
microbiological, molecular epidemiology and treatment of multidrug resistant tuberculosis 
(MDR-TB) cases in the UK and to determine factors associated with survival. The study was 
analyzed for three age categories (15-34years, 35-54years and 55
+
 years) resulted that survival 
was influenced by age. For those aged 15–34 years the median survival could not be calculated 
because, during the total study period, only 18.4% of the patients in this age group died that is, 
81.6% of patients were censored. For cases aged 35–54 years the median survival time was 1379 
days (95% CI 649 to 2066) with 50.0% cases censored, and in the 55+ age group the median 
survival time was 2515 days (95% CI 119 to 2515) with 45.5% censored.   
Marital status and Educational level 
Socio-Demographic Profile and Determinants of multidrug-resistant tuberculosis in patients who 
underwent first-line treatment in Addis Ababa: a case control study was conducted by Selamawit 
H. et al. (2012). They used multivariate logistic regression analysis to assess factors that 
determine the occurrence MDR-TB among patients who had taken first line anti-TB treatment in 
Addis Ababa City. They found the socio-demographic characteristics of MDR-TB patients and 
reviled that the marital status and educational level of the patients and found that 63.4% were 
single, 23.8% were married, 11.9% were Divorced and 0.75% were widow/widower. The 
educational level of MDR-TB patients were 11.2% were illiterate, 11.9% were read and write, 
20.1% were secondary school and 56.7% were educated tertiary and above. Results from the 
logistic regression analysis revealed that after adjusting for possible confounding factors  the 
study found that MDR-TB development is significantly associated education above 10th grade  
(AOR = 3.7; 95% CI; 1.1–12.1). 
Yanina B. et al. (2011) conducted a retrospective national cohort study on Survival of drug 
resistant tuberculosis patients in Lithuania. The cohort study consisted of a total of 1809 MDR 
TB confirmed patients.  They used Kaplan-Meier survival curves and multivariable Cox 
regression to describe the epidemiological, clinical and socioeconomic features and survival of a 
large national cohort of MDR-TB cases and to establish risk factors influencing their survival. 
The Socio-demographic results indicated that the majority of MDR-TB patients had primary or 
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secondary education label. The study also showed that adjust only for the effect of any treatment, 
lower levels of education at the time of MDR-TB diagnosis were independently associated with 
poorer survival times. 
Employment status and Religion 
A case-control study was conducted in Botswana, University of Pennsylvania Partnership, 
Gaborone, by N. M. Zetola et al. (2012), to describing the patterns of alcohol use among MDR-
TB patients and to determine whether alcohol use is associated with the development of MDR-
TB in Botswana. Multivariate logistic regression with MDR-TB case status to clearly identify the 
impact of alcohol use for the development of MDR-TB and a total of 114 cases were included in 
the study. The results have shown that most 79 (69.3%) of MDR-TB cases were Employed and 
35 (30.7%) of MDR-TB cases were unemployed. Another case-control study was conducted by 
the tuberculosis lead program medical research council, Pretoria, South Africa together with the 
International Research and Programs Branch, Division of TB Elimination, Centers for Disease 
Control and Prevention, Atlanta, Georgia, USA from 1999-2001. The objective of the study was 
to assess the factors associated with default from multi-drug tuberculosis treatment in South 
Africa by using multivariate logistic regression analysis the study was conducted to analyze 
different demographic and clinical variables. The results have shown that most 86 out of 96 
(90%) of the cases were Christians and the rest 10 out of 96 (10%) of the cases were non-
Christian. 
James C.M. Brust et al. (2010) employed multivariate logistic regression analysis and sensitivity 
analysis to study High Treatment Failure and Default Rates for Patients with MDR-TB in 
KwaZulu-Natal, South Africa. The study was conducted to describe treatment outcomes and 
determine risk factors associated with unfavorable outcomes among MDR-TB patients admitted 
to the provincial TB referral hospital in KwaZulu-Natal province, South Africa. The descriptive 
analysis shows that 277 (22.9%) of MDR-TB patients were Employed, 704 (58.2%) of MDR-TB 
patients were Unemployed, 228 (18.9%) of MDR-TB patients were Unknown employment 
status.     
2.4.2 Clinical factors 
Alcohol use 
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 Zetola N. et al. (2012) conducted a case control study on Alcohol use and abuse among patients 
with multidrug-resistant tuberculosis in Botswana. The study was conducted for the aim of 
describing the patterns of alcohol use among MDR-TB patients and to determine whether 
alcohol use is associated with the development of MDR-TB in Botswana. The case-control study 
considers a total of 114 cases and use conditional multivariate logistic regression with MDR-TB 
case status to clearly identify the impact of alcohol use for the development of MDR-TB. The 
results obtained indicated that 40 (35.1%) of MDR-TB patients use alcohol for their life time and 
the rest 74 (64.9%) were not for their life time. The study also identified alcohol abuse is 
prevalent among MDR-TB patients in Botswana and could be an important modifiable factor 
affecting health outcome in this population. In addition they found that MDR-TB subjects have 
an overall lower lifetime prevalence of any alcohol use than the non-alcohol user. Alcohol abuse 
is associated with the diagnosis of MDR-TB among people with TB.     
Another case-control study was conducted by the tuberculosis lead program medical research 
council, Pretoria, South Africa together with the International Research and Programs Branch, 
Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 
from 1999-2001. The objective of the study was to assess the factors associated with default 
from multi-drug tuberculosis treatment in South Africa. The study was conducted by using 
multivariate logistic regression analysis using SAS generalized linear models to assess the 
association of multiple factors with being a case patient (defaulter). The report showed that 33 
(38%) of the cases were use alcohol and 53 (62%) of the cases were not use alcohol. From the 
alcohol users 3 (3%) were daily drinker and 30 (35%) were occasionally drinker. The study 
reporting that any alcohol use during treatment was significantly associated with treatment 
default (UOR 1.7, 95% CI 1.02-2.9) leading that the use of alcohol on an occasional or regular 
basis was also more commonly reported by cases and 4% of the cases were missed treatment due 
to alcohol use.   
Presence of any chronic disease  
Matthew J. et al. (2014) conducted a cohort study between January 2009 and December 2011 
Diabetes Mellitus, Smoking Status, and Rate of Sputum Culture Conversion in Patients with 
Multidrug-Resistant Tuberculosis: A Cohort Study from the Country of Georgia. The aim of the 
study was to determine factors associated with culture conversion rates and estimate the 
association between DM and the risk of poor treatment outcomes among patients with MDR-TB. 
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Cox proportional hazards models were used to estimate hazard rate ratios (HR) and 95% 
confidence intervals (CI) for time to culture conversion. The results obtained show that Among 
1,366 patients with sputum culture conversion information, 966 (70.7%) had culture conversion 
and the median time to conversion was 68 days. The rate of conversion was similar among 
patients with MDR-TB and DM (adjusted hazard ratio [HR] 0.95, 95% CI 0.71–1.28) compared 
to patients with MDR-TB only. Another study also conducted by Xiaoliang Yuan et al. (2013) 
Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis 
in a tertiary care tuberculosis hospital in Chin. The retrospective study was conducted to analyze 
the clinical features of patients with MDR and XDR-TB from Jiangxi Province. The result 
obtained from the study shows that diabetes mellitus was the most common co-morbidity in 
MDR-TB (16/110, 14.5%) patients. 
Kang Y. et al. (2013) investigated Impact of diabetes on treatment outcomes and long-term 
survival in multidrug-resistant tuberculosis. MDR-TB patients newly diagnosed or retreated 
between 2000 and 2002 and followed for 8-11 years were retrospectively analyzed with respect 
to the effect of DM as co-morbidity on their treatment outcome and long-term survival. The aim 
of the study was to assess the impact of DM on treatment outcomes of patients with MDR-TB 
based on 1,407 patients with MDR-TB, 239 (17.0%) had coexisting DM. The mean age and 
body mass index were higher in MDR-TB patients with DM [MDR-TB DM positive] than in 
those without DM [MDR-TB DM negative]. Patients with MDR-TB and a co-morbidity of DM 
had a significantly lower treatment success rate than those without a history of DM (36.0 vs. 
47.2%, p = 0.002). In addition, DM was the negative predictor for MDR-TB treatment success in 
multivariate analyses [odds ratio 0.51, 95% confidence interval (CI) 0.26-0.99]. Mean survival 
times were also lower in MDR-TBDM positive than in MDR-TBDM negative patients (102 vs. 
114 months, p = 0.001), with DM as a significant predictor of poor long-term survival in 
multivariate analyses (hazard ratio 1.59, 95% CI 1.01-2.50). 
Therapeutic delay and Smear positivity 
Dhingra V. et al. (2007) conducted on outcome of multi-drug resistant tuberculosis cases treated 
by individualized regimens at a tertiary level clinic from August 2002 to December 2004. The 
study was conducted at New Delhi Tuberculosis (NDTB) Centre, a referral center for 
tuberculosis. All patients with pulmonary MDR-TB attending the outpatient MDR-TB clinic 
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from August 2002 – December 2004 were included to determine the clinical, radiological and 
drug resistance profile as well as the factors associated with treatment outcome of Multi-Drug 
Resistant Tuberculosis (MDR-TB). They used chi-square test to analyze the relation between the 
outcome of treatment and variables that might influence the outcome and some descriptive parts. 
The result of the study shows that over 70% patients were already resistant to three or more anti-
tuberculosis drugs at presentation. Out of the 27 patients, 13 were cured, 10 defaulted, one died, 
one is still on treatment with two referred for surgery and 12 patients were smear positive at the 
time of diagnosis. F Drobniewski et al. (2002) also conducted a national study of clinical and 
laboratory factors affecting the survival of patients with multidrug resistant tuberculosis in the 
UK and found that 78 out of 90 were sputum smear positive. 
Theodros G. et al. (2013) conducted survival and predictors of mortality among patients under 
multi-drug resistant tuberculosis treatment in Ethiopia: st. peter‟s specialized tuberculosis 
hospital, Ethiopia. A retrospective analysis of records was conducted from Oct, 2011 - May, 
2012 among cohorts of MDR-TB patients in St. Peter‟s specialized TB hospital that starts 
treatment from February 2009 and includes 188 MDR TB confirmed patients. The aim of the 
study was to assess survival and predictors of mortality among patients under MDR-TB 
treatment in Ethiopia: St Peter‟s specialized TB Hospital, Addis Ababa, Ethiopia. Relative risks 
(hazard ratio) with 95% CI and two-sided test of significance was used to measure the 
association of dependent and independent variables. Survival curves were compared between 
different exposure groups using log-rank test Survival trend over the follow up time was 
calculated using the Kaplan Meier (KM) method and the covariates were fitted to Cox 
proportional hazard regression model and Collett‟s Model selection approach was used. After 
fitting the Cox proportional hazard regression model to a set of survival data, the adequacy of the 
fitted model to the survival data was checked using (Generalized) Cox-Snell residuals and 
martingale residuals. The result of the socio-demographic and clinical characteristic of MDR-TB 
cases shows that 93 (49.47%) had therapeutic delay < 1 month and 95 (50.53) had therapeutic 
delay >= 1 month and showed significant association was therapeutic delay of more than one 
month. When they compare patient survival who starts treatment a month delay after diagnosed 
as MDR-TB was observed to have a higher hazard of death (HR= 3.61; 1.41- 9.20, P = 0.007).  
HIV status, MDR TB category and number of first line drugs at initiation  
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Telzak E. et al. (1998) dealt with predictors of multidrug-resistant tuberculosis among HIV-
infected patients and response to specific drug regimens in Bronx-Lebanon hospital center. The 
objective of the study was to determine the demographic,behavioral, clinical and geographic risk 
factor associated with the occurance of MDR-TB among HIV-infected patients and to evaluate 
the over all survival and clinical response of MDR-TB patients treated with specific drug 
regimens.    and fisher‟s exact test (two tail) were employed to determine statistical 
significance. Logistic regression analysis included all variables that on bivariate analysis were 
associated with MDR-TB with P value <0.2. for the treatment component,the cumulative 
probablities of survival (CPS) at 12 and 18 months were calculated by using the actuarial method 
of life table construction. The result of the study shows that the relationship between culture 
confirmed MDR-TB and several variables that were hypothesized to be risk factors for MDR-
TB. Prior anti-tuberculosis treatment was the only characterstic significantly associated with 
MDR-TB.Of the 23 patients who had received prior treatment , six (26%) had MDR-TB, 
compared with 10 (8%)of the 133 patients who had not received  prior treatment (odds ratio 
[OR] 4.3,95% confidence interval [CI] 1.4-13.5, P=0.02).on logistic regression analysis, 
including prior tuberculosis, place of birth and hospitalization within 6 months in a facility in 
which transmission of MDR-TB was known or suspected to have occurred, only prior 
tuberculosis treatment was found to be an independent predictor for MDR-TB (OR 4.6, 95% CI 
1.4-14.6, P=0.01). The only factor associated with the occurance of MDR-TB in their study was 
previous history of treatment for tuberculosis. Patients with MDR-TB were more than four times 
more likely to have had prior treatment compared to those with non MDR-TB patients. 
Previously treated patients had a 30% rate of MDR-TB compared with a 7% rate for those who 
had not received prior treatment. In a new York citywide survey of tuberculosis isolates from 
1991, 19% of patients had isolates that were resistant to at least both isoniazed and rifampin. In 
that study, a history of tuberculosis treatment was also the strongest predictor of MDR-TB. 
Previously treated patients had a 30% rate of MDR-TB compared with a 7% rate for those who 
had not received prior treatment. In a study of 34 HIV-infected patients with MDR-TB reported 
from Bronx-Lebanone Hospital center, an inner city facility in the south Bronx, the over all 
response rate was 50%. The median survival for these 34 patients was 315 days. Multivariate 
analysis revealed that receipt of appropriate therapy, defined as receiving  at least two drugs with 
in vitro activity against the isolate, for at least 2 consecutive weeks, was the only variable 
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associated with both initial and overall response. For the 20 patients who received two or more 
active drugs for at least 2 weeks, the CPS at 12 months was 82%. 
Songhua C. et al. (2013) conducted a case control study on Risk factors for multidrug resistance 
among previously treated patients with tuberculosis from July through August 2011 in five cities 
of Zhejiang Province in eastern China. The study aimed to ascertain the risk factors for MDR-TB 
in this particular population in China and used univariate analysis, the Chi-square test and 
Fisher‟s exact test, as well as the Student‟s t-test (two-sided), was performed to identify risk 
factors for MDR-TB, and a p-value less than 0.05 was considered statistically significant and a 
multivariate analysis was performed by forward stepwise (likelihood ratio) multiple logistic 
regression. In the forward stepwise regression, independent variables with a p-value less than 
0.10 were included in the logistic mode. The result of the study show that duration of first 
treatment of more than 8 months and having had more than three prior episodes of anti-TB 
treatment were associated with MDR-TB. 
Yanina B. et al. (2011) conducted a retrospective national cohort study on Survival of drug 
resistant tuberculosis patients in Lithuania. The national cohort study was conducted to describe 
the epidemiological, clinical and socioeconomic features and survival of a large national cohort 
of MDR/XDRTB cases and to establish risk factors influencing their survival. All MDR/XDRTB 
cases (n=1807, 1736 MDR-TB cases and 71 XDR-TB cases) reported from 2002 to 2008 in 
Lithuania with a known outcome were included in the survival analysis. They used Kaplan-
Meier survival curves and multivariable Cox regression to analyze time until death from any 
cause during patient‟s treatment or follow-up, from the time of the first-recorded diagnosis of 
MDR or XDRTB in the database. They found that a proportion of MDR-TB patients (13%) were 
resistant to other drugs in addition to resistance to isoniazid and rifampicin. The survival analysis 
revealed that Median survival for MDR TB patients was 4.0 (95% CI 3.7 to 4.4) years,  and for 
HIV positive versus HIV negative was 1.9 (95% CI 0.4 to 3.5) and 4.9 (95% CI 4.3 to 6.8) years, 
respectively. They also found that positive or unknown HIV status at the time of MDR-TB 
diagnosis was independently associated with poorer survival. HIV infection was associated with 
lower survival; only half survived for up to 1.9 years from MDR-TB diagnosis. They conclude 
that rapid identification of drug resistance, early administration of appropriate treatment, 
achievement of high cure rates, adequate infection control measures, expansion of HIV testing 
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and antiretroviral treatment are necessary to improve patients‟ survival and prevent further 
spread of MDR and XDR-TB in Lithuania. 
Samuel M. et al. (20013) conducted a study on Risk of death among HIV Co-Infected Multidrug 
Resistant Tuberculosis Patients, Compared to mortality in the general population of South Africa 
from 200-2004. The study covered a total of 2079 MDR-TB patients to determine excess 
mortality attributable to HIV among MDR-TB patients in South Africa using relative survival 
methods. A Poisson-based model was constructed to assess the excess mortality the relative 
survival time among HIV co-infected MDR-TB patients. Of the 1413 that were tested for HIV, 
554 (26.6%) were HIV positive, 859 (41.3%) were HIV negative and the rest 666 (32.1%) were 
unknown status of HIV. The study also showed that a large number of deaths, 169 (37.98%) 
deaths, were occurred on HIV positive MDR-TB patients.  The relative survival model showed 
that there was a significant difference in the survival of the patients in terms of their HIV status 
(p-value < 0.01). For comparative purposes, the results obtained from fitting logistic and 
proportional hazards regression models on the odds ratio (OR) and hazards ratio (HR) scales are 
clearly identified. The excess mortality rate was higher in HIV co-infected, than in HIV-
negative, patients (adjusted excess hazard ratio, 5.6 [95% CI, 3.2-9.7]) 
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CHAPTER THREE 
3. METHODOLOGY 
3.1 Introduction 
In this study, the methodology to be employed starting with description of study area and 
population, data and the description of the study variables are discussed. The study concludes 
discussing different statistical techniques used in the data analysis such as Kaplan-Meier survival 
analysis, Cox proportional hazard model and parametric survival regression models. 
3.2 Study Design  
This study was a retrospective cohort study based on data from the MDR-TB ward in Gondar 
university hospital.  The  study  reviewed patient‟s MDR-TB  charts,  intake forms  and  follow  
up  charts  of  MDR-TB  patients  in  Gondar University teaching hospital started MDR- TB 
treatment on August 2010 and followed until to August 2014. Each patient has one medical file 
containing all MDR-TB notes which includes the patient intake forms and MDR-TB care and 
follow-up card,  prepared  by  Federal  ministry  of  health  (EFMOH)  to  be uniformly  used  by  
clinicians  to  early  identify  and  document  clinical  and  laboratory variables. Thus,  in  this  
study  secondary  data  which was collected  from  patients  follow  up records are used. Based 
on this record of the patients, the variables which were important for the study were selected by 
using the patient‟s unique identification number or the laboratory code. This was done by 
communicating with the nurses and counselors to get the medical record and other important 
information for the study. 
3.3 Study area and its description  
The study was conducted at university of Gondar Hospital MDR-TB clinic.  The  university  of  
Gondar  Hospital  is  one  of  the  oldest  academic institutions  in  Ethiopia.  It has been 
producing a number of health professionals since more than half a century ago. The university is 
situated at the heart of  Gondar city  found  in Amhara  Region,  North  West of  Ethiopia,  which  
located  at  727  kilometers  away from  Addis  Ababa.  The hospital provides different inpatient 
and outpatient services to the population in the surrounding area of Gondar town and the nearby 
words and zones. 
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3.4 Data 
The target population for this study included all patients age ≥18 years with MDR-TB infection  
at Gondar University hospital MDR-TB clinic (which is located at Gondar town) in Amhara 
Region and started MDR TB treatment at Gondar hospital from period between August 2010 and 
August 2014 were followed for a maximum of 24 months. The target population for these studies 
was patients under MDR-TB treatment at Gondar university hospital started treatment since 
August 2010. The total number of population started MDR-TB treatment were 224 patients. 
From the total patients only 146 patients had a complete outcome and the remaining 78 patients 
were still on treatment and had no outcomes. To conduct the survival time and risk factor 
analysis, only patients who had known outcomes were taken and no samples were selected due to 
the fact that increasing the number of participants also increases the precision of the study. So, 
all patients who had known outcome were included in the study.    
3.5 data collection procedures 
The secondary data was collected using standardized structured data manipulation form in 
Gondar university teaching hospital. Relevant data was taken from MDR-TB follow up charts. 
The data were collected by two professional nurses and one more experienced nurse for 
supervision was involved. They all were professionals about MDR-TB and no training was given 
on the definition of variables on the data manipulation form. 
3.6 Variables of the study 
The response variable 
The response or outcome variable in this study is the survival time measured (in months) from 
the date of the MDR treatment‟s started until the date of the patient‟s death or censor 
(transferred, Dropout, Cured, Lost follow-up, treatment completed and treatment failed). 
Predictor Variables 
The predictor variables in survival data analysis are called covariates. These are explanatory 
variables which are assumed to influence the survival time of MDR-TB patients and are given 
below. 
Socio-demographic factors:  
 Sex of the patient 
 Age of the patient 
 Religion 
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 Marital status 
 Employment status 
 Educational level 
 Clinical factors:  
 HIV co-infection 
 MDR category 
  presence of chronic disease 
  clinical complication 
  No. Of resistant drugs at initiation 
  therapeutic delay 
 Alcohol use  
  smoking status  
  smear positivity  
Table 3.1: Description of the Independent variables 
Variables/factors Symbol of variable Categories 
Sex of the patient X1 Male 1 
  Female 0 
Age of the patient X2 
 
18-34 years 0 
35-54 years 1 
≥55 years 2 
Marital status 
(MRSUS) 
X3 Single 0 
Married 1 
Separated/Divorced 2 
Widow/  Widowed 3 
Education level 
(EDULABL) 
 
 
X4 Illiterate 0 
Read and write 1 
Secondary 2 
Tertiary and above 3 
Employment status 
(EMPSUS) 
X5 
 
Employed 0 
Own business 1 
Day  laborer 2 
Unemployed 3 
Religion X6 Orthodox 0 
Muslim 1 
Protestant 2 
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3.7 Survival Data Analysis 
 Survival analysis is the phrase used to describe the analysis of data in the form of time from a 
well-defined time origin until the occurrence of some particular event or end-point. Survival 
analysis is used to analyses data in which the time until an event is of interest. The response is 
often referred to as a failure time, survival time, or event time. Generally, survival analysis is a 
collection of statistical procedures for data analysis for which the outcome variable of interest is 
time until an event occurs (time-to-event data), which is always nonnegative and has a positively 
skewed distribution (Collett, 2003).  
One of the most important differences between the outcome variables modeled via linear and 
logistic regression analyses and the time variable in the survival data is the fact that we may only 
Others 3 
Therapeutic delay (DELAY) X7 >= 1 month 0 
< 1 month 1 
Number of first line drugs 
Resistant at 
initiation(NODRUG) 
X8 INH and RIF only 0 
>  INH and RIF 1 
Smoking status X9 Yes 0 
No 1 
Alcohol use 
 
X10 Yes 0 
No 1 
Any clinical complication 
(Clnccomplicn) 
 
X11 No complication 0 
Pneumonia 1 
Pneumothorax 2 
Hemoptysis 3 
Cor pulmonal 4 
MDR category (MDRCAT) 
 
X12 Previously treated 0 
Previously not  treated 1 
HIV co-infection (HIV) X13 Positive 0 
Negative 1 
Unknown 2 
Presence of any chronic disease 
(CHRONIC) 
X14 No chronic disease 0 
Diabetes mellitus 1 
Myocardial infarction 2 
Asthma 3 
DM and HTN 4 
Smear positivity X15 Positive 0 
Negative 1 
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observe the survival time partially. The variable time actually records two different things. For 
those subjects who experienced the event (died), it is the outcome variable of interest, the actual 
survival time. However, for subjects who have not experienced the even time (cured, lost follow 
up, transferred, treatment completed and treatment failed). These incomplete observations are 
referred to as being censored.  
There are generally three reasons why censoring might occur: when a subject does not 
experience the event before the study ends, an individual is lost to follow-up during the study 
period and a person withdraws from the study for known or unknown reasons. There are three 
categories of censoring. 
i)  Right censoring: Survival time is said to be right censored when it is recorded from 
its beginning to a defined time before its end time. This type of censoring is 
commonly recognized survival analysis and also considered in this study. 
ii)  Left censoring: Survival time is said to be left censored if an individual develops an 
event of interest prior to the beginning of the study; this is not common in survival 
studies. 
iii) Interval censoring: Survival time is said to be interval censored when it is only 
known that the event of interest occurs within an interval of time but the exact time of 
its occurrence is not known. 
3.7.1 Descriptive Methods for Survival Data 
Once we have collected time to event data, descriptive analysis for survival data is our first task 
to present numerical or graphical (using a survival curve) summaries of the survival times in a 
particular group. In general, a statistical analysis should begin with a thoughtful and thorough 
univariate description of the data. Survivor function and hazard function are the two functions of 
central interest in summarizing survival data.  
The Survival Function  
Let T be a random variable, which can take any non-negative value, associated with the actual 
survival times, t (time of death). When the random variable T has a probability distribution with 
underlying probability density function     , the distribution function (cumulative distribution 
function) of T is then given by: 
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    = P (T<t) =∫       
 
 
,   t  0                                                                                       (3.1)                             
Which represents the probability that a subject selected at random will have a survival time less 
than some stated value t. Then, the survival function      is defined as: 
                                = P (T t) = 1 -                                                                              (3.2) 
The survivor function can therefore be used to represent the probability that an individual 
survives from the time origin to sometime beyond t. The survival function is the probability that 
an individual will survive at time t or beyond t, and then relationship between the probability 
density function f(t) and S(t) will be: 
                 f(t)=  
         
  
  
      
  
                                                                                        (3.3)     
The Hazard Function  
The hazard function is widely used to express the risk or hazard of experiencing the event (death) 
at some time t, and is obtained from the probability that an individual experiencing the event at 
time t, conditional on he or she has survived (censoring) to that time. That is, the function 
represents the instantaneous failure rate for an individual surviving to time t.  
The hazard function      is defined by:                                                   .            
          
    
                                                                            
  
 
            
    
  [            ]
  
                                                                                        
By applying the theory of conditional probability and the relationship in equation (3.3), the 
hazard function can be expressed in terms of the underlying probability density function and the 
survivor function as follows (Collett, 2003). 
                                       = 
    
    
  - 
 
  
                                                                        (3.5)  
The corresponding cumulative hazard function H   is defined by: 
H    ∫       
 
 
                                                                        (3.6) 
Hence the survival function can be rewritten as 
    = exp       ,                                                                                    (3.7) 
The hazard rate is not a probability, it is a probability rate. Therefore it is possible that a hazard 
rate can exceed one in the same fashion as a density function f (t) may exceed one. 
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Survival data are summarized through estimates of the survival and hazard function. The Kaplan-
Meier, Nelson-Aalen and Life Tables are the three commonly used methods for estimating 
survival and hazard functions (Collett, 2003). 
3.7.1.1 Kaplan-Meier Estimator  
The first step in the analysis of ungrouped censored survival data is normally to obtain the 
Kaplan-Meier estimate of the survivor function. The Kaplan-Meier estimator is the standard 
estimator of the survival function (Collett, 2003). This estimator is also known as the product-
limit estimator of the survivor function. The Kaplan-Meier estimator is used to estimate the 
survival time (time of censoring) of a patient and construct survival curves to compare the 
survival experience of a patient between different categorical variables.  
This method is non-parametric or distribution-free since it does not require specific assumption 
to be made about the underlying distribution of the survival times.  
Suppose the data consist of n survival times t1, t2,…,tn and some of these observations are right-
censored times, i.e. for some of the tj, it is only know that individual j was still censoring at time 
tj. Let r be the number of distinct failure times, r ≤ n, and t(1) < t(2)<……<t(r) be the ordered 
failure times. And assume that      is the number of patients at censored just before t(j)  and      is 
the number of patients who was died at time t(j) .  Then the Kaplan-Meier estimator of the 
survival function at time t is given by:    
                   ̂    ∏{
     
  
}
 
   
                                                                                                                  
                         for t(k) ≤ t(k+1) , k=1,2,…,r, with   ̂(t)=1 for t < t(1). 
 
The standard error of the Kaplan-Meier survival estimator is estimated using Greenwood‟s 
formula (Collett, 2003) given as: 
                       Se { ̂(t)}  ̂(t){∑
                       
  (        )
 
   }
 
   
                                                                    (3.9) 
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 3.7.1.2. Comparing Survival Distributions 
After providing a description of the overall survival experience in the study, we turn our 
attention to a comparison of the survivorship experience in key subjects in the data. When 
comparing groups of subjects, it is always a good idea to begin with a graphical display of the 
data in each group. The simplest way of comparing the survival times obtained from two or more 
groups graphically is to plot the Kaplan-Meier curves for these groups on the same graph. The 
figure in general shows if the pattern of one survivorship function lies above another, meaning 
that the group defined by the upper curve lived longer, or had a more favorable survival 
experience, than the group defined by the lower curve. However, this graph does not allow us to 
say, with any confidence, whether or not there is a real difference between the groups. The 
observed difference may be a true difference, but equally, it could also be due merely to chance 
variation. Assessing whether or not there is a real difference between groups can only be done, 
with any degree of confidence, by utilizing statistical tests. 
A number of statistical tests have been proposed to assess the real difference between groups 
such as Log-rank, Generalized Wilcoxen, Tarone-Ware test and so on (Hosmer and Lemeshow, 
1989). The calculation of each test is based on a contingency table of groups by status at each 
observed survival time. The general form of these test statistics for the comparison of survival 
functions between two groups can be defined (Hosmer and Lemeshow, 1989) as follows:       
                      
*∑   (       ̂   )
 
   +
 
∑   
  ̂  
 
     
                                                                                                                                                                                                                                                
where 
r   is the number of rank-ordered failure times (event times). 
    is the weight for censor adjustment at time t(j) . 
 ̂  = 
       
  
= is the expected number of individuals who experienced an event at time t(j) in 
group 1,  ̂  =
                  
         
= is the variance of the number of event occurred at time t(j)  
in group 1,      is the observed number of failure (event occur)  at time t(j) in group 1,  n1j  
is the number of individuals at risk of event occur in the first group just before time t (j),  
n2j  is the number of individuals at risk in the second group just before time t(j),  dj   is the 
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total number of events occurred at t(j),  nj  is the total number of individuals  at  risk 
before time t(j). 
Under the null hypothesis that the two survivorship functions are the same, and assuming that the 
censoring experience is independent of group, and that the total number of observed events and 
the sum of the expected number of events is large, Q follows a chi-square distribution with one 
degree of freedom (Hosmer and Lemeshow, 1989).  
The most frequently used test is the log-rank test (sometimes called the Mantel-Haenszel test 
and Cox Mantel log-rank test). This test is based on weights equal to one, i.e.     1.  The log-
rank test is a non-parametric test for comparing two or more independent survival curves. Since 
it is a non-parametric test, no assumptions about the distributional form of the data need to be 
made. For the comparison of two groups of survival data the log rank test statistic is given 
(Hosmer and Lemesho, 1989) by; 
    
[∑ (        ̂   )
 
   ]
 
∑  ̂  
 
   
                                                                                                               
                                                                                                             
The statistic     follows a chi-square distribution with one degree of freedom. It tests the extent 
to which the observed survival times in the two groups deviate from those expected under the 
null hypothesis of no group differences. 
Breslow’s test (also known as Gehan‟s generalised Wilcoxon test) (Collett, 2003) is applicable 
to data where there is progressive censoring. It is more powerful than the log-rank test when the 
hazard functions are not parallel and where there is little censoring. It has low power when 
censoring is high. It gives more weight to early failures.  
The Wilcoxon test statistic:                               
                    
[∑   (        ̂   )
 
   ]
 
∑   
  ̂  
 
   
                                                                     
 has a chi-square distribution with one degree of freedom under  the null hypothesis that the two 
survivorship functions are the same, assuming that the censoring experience is independent of 
the group and the total number of observed events and the sum of the expected number of events 
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is large . This test uses weights equal to the number of subjects at risk at each survival time, i.e. 
  =  . 
The log-rank test and Wilcoxon test can easily be generalized to the comparison of more than 
two groups. The statistic for g > 2 groups follows an approximate    distribution with g−1 
degrees of freedom when the null hypothesis of no group difference is true (Collett, 2003). 
Of the two, the log-rank test is the more suitable when the alternative to the null hypothesis of no 
difference between two groups of survival times is that the hazard of death at any given time for 
an individual in one group is proportional to the hazard at that time for a similar individual in the 
other group. This is the assumption of proportional hazards, which underlies a number of 
methods for analyzing survival data. For this reason we use the log-rank test to compare the 
MDR TB experience among different groups. 
3.7.2 Modelling Survival Data 
The non- parametric methods (for instance, Kaplan-Meier, Log-rank test) described above can be 
useful in the analysis of a single sample of survival data, or more groups of survival times. 
However, in most medical studies that give rise to survival data, supplementary information will 
also be recorded on each individual. The method (non-parametric method) discussed so far are 
not suitable for such data set. In order to explore the relationship between the survival experience 
of individual and explanatory variables, an approach based on statistical modeling can be used 
(Collett, 2003). 
Through a modeling approach to the analysis of survival data, we can explore how the survival 
experience of a group of individuals depends on the values of one or more explanatory variables, 
whose values have been recorded for each individual at the time origin.  
There are two broad reasons for modeling survival data.  One objective of the modeling process 
is to determine which combination of potential explanatory variables affects the form of the 
hazard function. Another reason for modeling the hazard function is to obtain an estimate of the 
hazard function itself for an individual.  
A variety of models and methods have been developed for doing this sort of survival analysis 
using either parametric or semi-parametric approaches. Semi-parametric models are models that 
parametrically specify the functional relationship between the lifetime of an individual and his 
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characteristics (demographic, socio-economic, etc.) but leave the actual distribution of lifetimes 
arbitrary. The most popular semi-parametric model is the proportional hazards model (Collett, 
2003).  
3.7.2.1 The Cox Proportional Hazards Regression Model  
The basic model for survival data is the proportional hazard model. This model was proposed by 
Cox (1972) and has also come to be known as the Cox regression model. Although the model is 
based on the assumption of proportional hazards, no particular form of probability distribution is 
assumed for the survival times. The model is therefore referred to as a semi-parametric model.  
The net contribution of socio-demographic variables on experience to an event (death) was 
assessed by using the Cox proportional hazard model, which combines the features of life table 
and regression (Cox, 1972). 
Cox (1972) proposed a semi-parametric model for the hazard function that allows the addition of 
covariates, while keeping the baseline hazards unspecified and can take only positive values. 
With this parameterization, the Cox hazard function is specified as a function of time and the 
covariates:  
                                                                                                                 (3.13) 
where,       is the baseline hazard function that characterizes how the hazard function changes 
as a function of survival time,           represents the hazard function at time t with covariates 
X =                                is a column vector of p regression parameters, 
         characterizes how the hazard function changes as a function of subject covariates.  The 
model (3.13) is referred to as Cox model, or Cox proportional hazards model or simply the 
proportional hazards model. There are two assumptions of proportional hazards model. The first 
assumption is the proportional hazard assumption. The assumption of proportional hazards is that 
the hazard of occurrence of an event at any given time for an individual in one group is 
proportional to the hazard at that time for an individual in the other group. When there are 
covariates in the analysis, which are times dependent, this assumption may not hold. This can be 
verified by considering the hazard ratios of different individuals (Collett, 2003). 
For two different individuals with covariates X1 = (x11,x12,…, x1m)
׳   
and X2 = (x21,x22,…, x2m)
׳
, the 
proportion 
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called the hazards ratio, and clearly this ratio is independent of time which means that the log 
hazard ratio is constant at any given time.                                                                                                                                                                                                                               
The second assumption is that the relationship between log hazard or log cumulative hazard and 
a covariate is linear. The Cox proportional hazards model can equally be regarded as linear 
model, as a linear combination of the covariates for the logarithm transformation of the hazard 
ratio given by: 
   {
        
     
}     {    }                                                                     
The quantity                      is called the linear combination of the Cox 
proportional hazards model. 
The hazard function in the Cox model is called semi-parametric function since it does not 
explicitly describe the baseline hazard function, ho(t). The survival function of the proportional 
hazard model is estimated as: 
                                                                                                                             (3.16)                           
Where,          is the cumulative hazard function at time t for a subject with covariate x. 
Since we have assumed that survival time is absolutely continuous, the value of the cumulative 
hazard function is expressed as: 
                                                                                                                    (3.17) 
Consequently, from the proportional hazards function, we obtained the survivor function given 
by: 
                             [     ]                                                                                     (3.18) 
Where,       is the baseline cumulative hazard function and       is the baseline survival 
function (Collett, 2003). 
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3.7.2.2 Fitting the Cox Proportional Hazard Regression Model 
Fitting the Cox model to observed survival data requires estimating the unknown regression 
coefficients ( ). Also, the baseline hazard function must be estimated. It turns out that these two 
components of the model can be estimated separately. The coefficients should be estimated first 
and the estimates are then used to construct an estimate of the baseline hazard function. The 
regression coefficients in the proportional hazards Cox model, which are the unknown 
parameters in the model, can be estimated using the method of maximum likelihood (Collett, 
2003). 
In Cox proportional hazards model we can estimate the vector of parameters β without having 
any assumptions about the baseline hazard,       . As a consequence, this model is more flexible 
and an estimate of the parameters can be obtained easily (Collett, 2003). 
 Full Maximum Likelihood Estimation  
Suppose the survival data based on n independent observations are denoted by the triplet (ti, δi, 
Xi), i=1, 2... n. 
 where 
ti is the survival time for the i
th
  individual. 
δi is an indicator of censoring for the i
th
 individual. given by 0 for censored and 1 for 
event experience. δ = 1, the actual survival time for the ith individual whose death was 
occurred , and the exact duration of death  was known at the time of the survey) and δ = 
0, censored survival time (Censored observations were those in which the patients  were 
not died  at the time of survey). 
Xi = (Xi1, Xi2... Xim) 
  
is a column vector of m covariates for individual i. 
The full likelihood function for right censored data can be constructed as: 
  
              ∏                      
 
   
                                                                                              
   Where,            =        
     is the hazard function for the i
th
 individual. 
               = [      ]          is the survival function for the ith individual.  It follows that                
                 ∏ [        
    ]
  
[      ]                                                                                                                   
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The full maximum likelihood estimator of β can be obtained by differentiating the right hand 
side of equation (3.20) with respect to the components of β and the base line hazard      . 
This implies that unless we explicitly specify the base line hazard      , we cannot obtain the 
maximum likelihood estimators for the full likelihood. To avoid the specification of the base line 
hazard, Cox (1972) proposed a partial likelihood approach that treats the baseline hazard as a 
nuisance parameter and removes it from the estimating equation (Collett,  2003). 
Partial Likelihood Estimation 
Instead of constructing a full likelihood, we consider the probability that an individual 
experiences an event at time t(i)  given that an event occurred at that time. 
Suppose that data are available for n individuals, amongst them there are r distinct failure times 
and n - r right-censored survival times, and assume that only one individual was died at each 
ordered failure time, so that there are no ties. The r ordered failure times will be denoted by t(1) 
<t(2)<….< t(r), so that t(i) is the i
th 
ordered failure time. The set of individuals who are at risk at 
time t(i) is the i
th
 ordered failure (experiences an event)  time, and denoted by R (t(i)). And let X(i) 
be the vector of explanatory variables for an individual who experiences an event  at t(i).  
The partial likelihood function is derived by taking the product of the conditional probability of a 
failure at time t(i), given the number of individuals who are at risk of experiencing the event at 
time t(i).  Then the probability that the j
th
 individual will experience an event at time t(i) is given 
by:                                                     .                             
           
           
∑                    
                                                                                                                                                                                           
Where, the summation in the denominator is over all individuals in the risk set.  
Thus the partial likelihood is the product over all event time t(i ) for i = 1,2,...,r of the conditional 
probability (3.20) to give the partial likelihood function and  can be expressed in the form  
                                     ∏[
           
∑                    
]
 
   
                                                                   
The product is over the r distinct ordered survival times. The corresponding log-partial likelihood 
function is given by: 
                      ∑ { 
         [∑                    ]}
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The partial likelihood derived above is valid when there are no ties in the data set. But in most 
real situations tied survival times are more likely to occur.  
In addition to the possibility of more than one experience an event at a time, there might also be 
more than one censored observations at a time of event. To handle this real-world fact, partial 
likelihood algorithms have been adopted to handle ties. 
There are three approaches commonly used to estimate regression parameters when there are 
ties. 
These are Breslow (1974), Efron (1977), and Cox (1972) approximations (Collett, 2003).The 
most popular and easy approach is Breslow‟s approximation. In many applied settings there will 
be little or no practical difference among the estimators obtained from the three approximations. 
Because of this, and since the Breslow approximation is more commonly available, unless stated 
otherwise, analysis presented in this study will be based on it. 
The Breslow Approximation 
This approximation is proposed by Breslow and Peto by modifying the partial likelihood which 
takes the following form 
                          ∏
         
[∑                    ]
  
                                                                                                                         
 where  si is  the sum of covariates over di subjects at time t(i). 
 di is the number of experienced an event occurred at time t(i). 
Now the partial log likelihood of (3.24) is given as                                               .   
          ∑[ 
           ∑          
          
 ]
 
   
                                                                   
We obtain the Breslow maximum partial likelihood estimator, adjusted for tied observation, by 
differentiating equation (3.25 ) with respect to the component of β and setting the derivative 
equal to zero and solving for the unknown parameters. 
When there are no ties, that is, when di = 1 for each event time, the approximation in equation 
(3.24) reduce to the likelihood function in equation (3.22). 
 The maximum likelihood estimates of the regression parameters in the proportional hazards 
model can be found by maximizing the log-likelihood function in equation (3.23) using 
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numerical methods. This maximization is accomplished using the Newton-Raphson procedure 
(Collett, 2003).  
The Newton-Raphson procedure is used to maximize the partial likelihood function (3.23) based 
on the following iterative procedure. An estimate of the vector of β-parameters at the (s+1)th 
cycle of iterative procedure,  ̂   , is given by: 
     
    ̂   = ̂ + 
  ( ̂ )U( ̂ ),       for s = 0, 1, 2, ......                                                      (3.26)                                                                                    
Where U( ̂    is the     vector of first derivatives of the log-likelihood function in equation 
(3.23) with respect to the β-parameters and this quantity known as the vector of efficient scores 
evaluated at  ̂ . 
 (β) = - 
           
      
  is the     matrix and known as observed information matrix.  
   (  ̂   is the inverse of the observed information matrix evaluated at  ̂ . The variance-
covariance matrix of   ̂     ( ̂)  can be approximated by the inverse of the information matrix 
evaluated at  ̂  i.e.  
  ( ̂    
The process can be started by taking  ̂ =0 and continue until the change in the likelihood 
function is sufficiently small, that is, when  ̂   and   ̂    are sufficiently close together.  
3.7.2.3 Variable Selection Procedures 
In many settings a variety of explanatory variables are measured and a major question in 
analyzing such data sets is how to incorporate these variables in the modeling procedure. An 
initial step in the model selection procedure is to identify a set of explanatory variables that have 
the potential for being included in the linear component of the proportional hazards model. The 
methods available to select a subset of the covariates to include in a proportional hazards 
regression model are essentially the same as those used in the other regression models, like 
purposeful selection, stepwise (forward selection and backward elimination) and best subsets 
selection. 
When the number of variables is relatively large, it can be computationally expensive to fit all 
possible models. In this situation, automatic routines for variable selection that are available in 
many software packages might seem an attractive prospect. These routines are based on forward 
selection, backward elimination or a combination of the two known as the stepwise procedure. 
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These automatic routines have a number of disadvantages. Typically, they lead to the 
identification of one particular subset, rather than a set of equally good ones. The subsets found 
by these routines often depend on the variable selection process that has been used, that is, 
whether it is forward selection, backward elimination or the stepwise procedure, and generally 
tend not to take any account of the hierarchic principle. They also depend on the stopping rule 
that is used to determine whether a term should be included in or excluded from a model. Thus, 
instead of using automatic variable selection procedures, the following general strategy for 
model selection is recommended by Collet (2003). 
1. The first step is to fit models that contain each of the variables one at a time. The values 
of       ̂ for these models are then compared with that for the null model. The null 
model is a model in which there are no explanatory variables in the linear component of 
the hazard model and used to determine which variables on their own significantly reduce 
the value of -2log ̂. 
2. The variables that appear to be important from step 1 are then fitted together in a 
multivariable model. In the presence of certain variables others may cease to be 
important. Consequently, those variables that do not significantly increase the value of 
      ̂  when they are omitted from the model can now be discarded. We therefore 
compute the change in the value of       ̂  when each variable on its own is omitted 
from the set. Only those that lead to a significant increase in the value of       ̂  are 
retained in the model. Once a variable has been dropped, the effect of omitting each of 
the remaining variables in turn should be examined. 
3. Variables that were not important on their own, and so were not under consideration in 
step 2, may become important in the presence of others. These variables are therefore 
added to the model from step 2, one at a time, and any that reduce       ̂  significantly 
are retained in the model. This process may result in terms in the model determined at 
step 2 ceasing to be significant. 
4.  A final check is made to ensure that no term in the model can be omitted without 
significantly increasing the value of      ̂, and that no term not included significantly 
reduces       ̂  . 
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When using this selection procedure, rigid application of a particular significance level should be 
avoided. In order to guide decisions on whether to include or omit a term, the significance level 
should not be too small. A level of around 20% - 25% is recommended.   
3.7.3 Assessment of Model Adequacy 
The adequacy of the model needs to be assessed after the model has been fitted to observed 
survival data.  Model-based inferences depend completely on the fitted statistical model. For 
these inferences to be valid, the fitted model must provide an adequate summary of the data upon 
which it is based. Indeed, the use of diagnostic procedures for model checking is an essential part 
of the modeling process.  
As model assumptions checking are based on residuals, we will first introduce the different types 
of residuals used in survival analysis, and more specifically in the semi-parametric proportional 
hazards model. Residuals are values that can be calculated for each observation and have the 
feature that their behavior is known, at least approximately, when the fitted model is satisfactory.  
Different types of residuals are typical for survival analysis due to the fact that censoring has to 
be taken into account. Ordinary residuals from linear or generalized linear models are therefore 
often not applicable. 
Cox-Snell Residuals 
The residual that is widely used in the analysis of survival data is the Cox-Snell residual, so 
called because it is a particular example of the general definition of residuals given by Cox and 
Snell (1968). The Cox-Snell residual for the i
th
 individual,  i=1, 2, ..., n, is given by: 
          ̂
   ) ̂ (ti)                                                                                  (3.27) 
where   ̂ (ti) is an estimate of the baseline cumulative hazard function at time t i, the observed 
survival time of  that individual. Note that from equation (3.27), the Cox-Snell residual,    , is 
the value of    ̂ (ti) =      ̂     , where  ̂ (ti) and  ̂      are the estimated values of the 
cumulative hazard and survivor functions of the i
th
 individual at  ti.  
In the argument, if the model fitted to the observed data is satisfactory, then the model-based 
estimate of the survivor function for the i
th
 individual at ti, the survival time of that individual, 
will be close to the corresponding true values Si(ti). If the observed survival time for an 
individual is right-censored, the corresponding value of the residual is also right censored. The 
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residual will therefore be a censored sample from the unit exponential distribution, and a test of 
this assumption provides a test of model adequacy. Furthermore, since the Cox-Snell residuals 
are assumed to have an exponential distribution when an appropriate model has been fitted, they 
have a highly skewed distribution. 
Censored observations lead to residuals that cannot be regarded on the same footing as residuals 
derived from uncensored observations. Therefore to take an account for censoring, the modified 
Cox-Snell residual, known as martingale residual, is used. 
Martingale Residuals 
For the i
th
 individual, i=1,2,…,n, the martingale residuals are  given by: 
                             rmi = δi – rci                                                                                                (3.28) 
Where,     is event indicator, which takes the value zero if the observed survival time of the i
th 
individual is censored and unity if it is uncensored. 
Martingale Residuals take values in (- ; 1] and are always negative for censored observations. 
In large samples, the martingale residuals are uncorrelated with one another and have expected 
value of zero. However, the martingale residuals are not symmetrically distributed about zero. 
Schoenfeld Residuals  
 Two disadvantages of Cox–Snell residuals and Martingale residuals are that they depend heavily 
on the observed survival time and require an estimate of the cumulative hazard function. Both of 
these disadvantages are overcome in a residual proposed by Schoenfeld (1982). These residuals 
were originally termed partial residuals, but are now commonly known as Schoenfeld residuals.  
Schoenfeld residual differs from those considered previously in one other important respect. This 
is that there is not a single value of the residual for each individual, but a set of values, one for 
each explanatory variable included in the fitted Cox regression model. 
The i
th
 partial or Schoenfeld residual for Xj, the j
th
 explanatory variable in the model, is given by:  
                                rpji  =     {xji -  ̂  },                                                                                 (3.29) 
Where, Xji is the value of the j
th
 explanatory variable, j=1, 2,…,p, for the ith individual in the 
study, and if individuals in the risk set are indexed by l, then: 
 ̂   
∑       ( ̂  )       
∑    ( ̂  )       
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And R(ti) is the set of all individuals at risk at time of ti. 
Schoenfeld residuals are also used to check the proportionality of the covariates over time that is 
to check the validity of the proportional hazards assumption. If the model fits well then the 
residuals are randomly distributed without any systematic pattern around the zero line, reference 
line. 
3.7.3.1 Overall Goodness of Fit 
One method of checking goodness of fit of the model is to use R
2
. In proportional hazards 
regression model as in all regression analyses there is no single, simple method of calculating 
and interpreting R
2
, because in Cox proportional hazards model, R
2 
depends on the proportion of 
the censored observations in the data. A perfectly adequate model may have what, at face value, 
seems like a terribly low R
2
 due to high percent of censored data (Hosmer and Lemeshow, 1998). 
The measure of goodness of fit R
2
p based on partial likelihood is given by:- 
  
  =1- exp [
 
 
(LO - Lp)]                                                                                   (3.31) 
where,  
Lo is the log partial likelihood for empty/null model, the model with no covariates. 
Lp is log of partial likelihood for the fitted model with p covariates, and n is the 
total number    of observations in the model. 
Under the assumption of proportional hazards, there are three different tests for model 
assessment (the significance of the coefficients): the partial likelihood ratio test, the Wald test 
and the score test (Hosmer and Lemeshow, 1998). 
Partial Likelihood Ratio Test 
Partial likelihood ratio test is the easiest test to compute and the best of the three tests for 
assessing the significance of the fitted model (for testing the significance of a subset of q 
explanatory variables from p explanatory variables) (Hosmer and Lemeshow, 1998).  
The partial likelihood ratio test statistic,   , is given by: 
                                   ( ̂)                                                                                (3.32) 
Where,      ( ̂) is the log-partial likelihood evaluated at  ̂ and                    is the 
log-partial likelihood evaluated at     . 
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Under the null hypothesis, Ho:               that all q coefficients are simultaneously 
equal to zero, and under mathematical regularities and large sample size conditions     follows a 
chi-square distribution with q degree of freedom,   
 . 
Wald test 
The Wald test is used to check the overall goodness of fit as well as checking the significance of 
each parameter of the model.  
Under the hypothesis, Ho:                      vs H1: at least one    ,  ̂  will be 
asymptotically normally distributed with mean 0 covariance matrix estimated by  ̂ar(  ̂ ) = 
 ( ̂)
  
. Then, the Wald test statistic,    ,  given by: 
                    ( ̂    )
 
 ( ̂)
  
( ̂    )   ̂
  ( ̂)
  
 ̂                                                     (3.33) 
follows a chi-square distribution with q degree of freedom,      . 
Score test  
The score test statistic, to test H0:    = 0 = (0, 0, 0….0)' q × 1 is defined as 
              
                                                                        (3.34) 
Where,      and      
  are the score vector and inverse of the observed information matrix 
evaluated at   . Under null hypothesis and for large sample    is asymptotically distributed as 
chi-squared with q degree of freedom,   
 . 
3.7.3.2 Checking for the Proportional Hazards Assumption 
Once a suitable set of covariates has been identified, In order to use the Cox model, it is wise to 
check each covariate to ensure that the proportional hazards assumption is valid. This is a critical 
assumption of proportional hazards model and must be checked for each covariate. To assess the 
proportional hazards assumption we examine the extent to which the estimated hazard curves for 
each level of strata of a covariate are equidistant over time. Different tests and graphical 
techniques have been developed to check whether the proportional hazards assumption holds. 
The Grambsch-Therneau test of non-proportionality uses partial residuals for the test of 
proportional hazards assumption. In order to use this test for the i
th
 covariate,     Grambsch and 
Therneau (1994) propose a time-varying coefficient as: 
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                                                                                                                                       (3.35) 
Where,       is time varying coefficient,    is constant,      is some specified function of time, 
usually            . The Cox proportional hazard model for time varying coefficient with 
            becomes 
 (          )                    
Substitute                   gives      
                                                        (          )                          
                                                                                                                                                                      
This looks like the proportional hazards model where the interaction term,    ln(t) is included in 
the model in addition to the main effect    . To test the significance of the interaction term    
ln(t), that is,    :       against          we can use Wald and/or Likelihood Ratio tests. If 
      is not rejected,   
   are not time varying coefficients and hence the proportional hazards 
assumption is satisfied. If      is rejected then the proportional hazards assumption is not 
satisfied. 
The Schoenfeld residuals graphical technique can be used to assess Cox model assumptions. For 
greater diagnostic power the scaled schoenfeld residual is preferred. The scaling can be done on 
the variance of the i
th
 subject Schoenfeld residuals. If the plot of scaled Schoenfeld residuals 
versus the logarithm of time is a random, smooth, straight line about zero the proportional 
hazards assumption will be satisfied. 
3.7.3.3 Checking for Linearity of Continuous Covariates 
The assumption of linearity can be checked by using the plot of martingale residuals. The plot of 
martingale residuals obtained from fitting the model, excluding the covariate whose functional 
form needs to be determined, against the excluded covariate display the functional form required 
for the covariate. If the resulting plot is random showing no systematic pattern and the smoothed 
plot is a horizontal straight line. This indicates that the covariate is linear in the model. 
3.7.3.4 Extensions of the Proportional Hazards Model 
We have used a proportional hazards model with a common unspecified baseline hazard function 
where all the study covariates had values that remained fixed over the follow-up period (i.e. the 
effect of a given covariate not changing over time). If the assumption of proportionality is 
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violated, the simple Cox regression model is invalid and more complicated analyses such as the 
stratified Cox regression model or the extended Cox regression model is required. Then to 
accommodate non-proportionality assumption one can apply stratified proportional hazards 
model in which the stratification in most cases is done by using a covariate fixed by design 
(Nihal and Tekin, 2007). 
 The stratified Cox regression model is a modification of the Cox regression model by the 
stratification of a covariate that does not satisfy the proportional hazards assumption. Covariates 
that are assumed to satisfy the proportional hazards assumption are included in the model, 
whereas the predictor being stratified is not included (Nihal and Tekin, 2007). 
Let k covariates fail to satisfy the proportional hazards assumption, and p covariates satisfy 
proportional hazards assumption. The covariates not satisfying the proportional hazards 
assumption are denoted by Z1, Z2, … ,Zk and the covariates satisfying the proportional hazards 
assumption are denoted by X1, X2, …, Xp. To form the stratified Cox regression model, a new 
variable is defined from z variables and denoted by z*. The stratification variable z* has k* 
categories, where k* is the total number of combinations (strata) formed after categorizing each 
of z's.  The stratified cox regression model is defined (Klein et al, 1997) as: 
                                                                                                                       (3.37) 
Where, the subscript g represents the strata. The strata are the different categorizations of the 
stratum variable.  
The variable z* is not implicitly included in the model, whereas the x's which are assumed to 
satisfy the proportional hazards assumption are included in the model. The baseline hazard 
function,       , is different for each stratum. However, the coefficient vector   is the same for 
each stratum. Since the coefficients of the x's are the same for each stratum, the hazard ratios are 
same for each stratum. 
The form of the partial likelihood for the g
th
 stratum is identical to the partial likelihood used in 
proportional hazards model, but it includes an additional subscript, g, indicating the stratum. The 
contribution to the partial likelihood for the g
th
 stratum is 
       ∏[
          
∑                   
]
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Where,    : the number of observations in the g
th
 stratum 
     The i
th
 observed value of time in g
th
 stratum 
    : The value of the censoring indicator associated with     
       : The risk set for subjects in stratum s at time     
    : The vector of p -covariates for subject i in stratum g . 
The full stratified partial likelihood is obtained by multiplying the contributions to the likelihood, 
namely 
      ∏      
 
   
                                                                                                                                 
The maximum stratified partial likelihood estimator of the parameter vector, β, is obtained by 
solving the p equations obtained by differentiating the log          with respect to the p 
unknown parameters and setting the derivatives equal to zero. Finally model building and model 
assessment is the same as that of proportional hazards model. 
3.7.3.5 Interpretation of the Coefficients of the Final Cox-Regression Model 
When the proportional hazards Cox model is used in the analysis of survival data, the coefficient 
of the explanatory variables in the model can be interpreted as the logarithm of the ratio of the 
hazard of death of the      group to the baseline (reference group) hazard. The higher the hazard 
ratio the lower is the survival probability, and vice versa. If for an exposed group the hazard ratio 
is high, the survival probability would be equivalently low. In addition, the parameter       can 
be interpreted as the rate of change in log (HR) per unit change in the     covariate. 
3.8 Parametric Survival Regression Models 
In previous topics it was focused entirely on the use of semi-parametric model, proportional 
hazards Cox regression model, in the analysis and prediction of the survival time of MDR TB 
patients. The basis of this method is to avoid having to specify the hazard function completely. 
However, there may be setting in which the distribution of the survival time is in specific 
parametric distribution that justifies the use of a fully parametric model to better address the goal 
of the analysis. A parametric survival model assumes that the survival time follows a known 
distribution. The popularity of this approach is due to the fact that plausible models may be 
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easily fit, evaluated and interpreted. Many models using different distributions have been 
developed. Some of most common survival models are: 
3.8.1. The Exponential Survival Regression Model 
The simplest model for the hazard function is to assume that it is constant over time. The hazard 
of death at any time after the time origin the study is then the same, irrespective of the time 
elapsed (Collett, 2003). Under this model, the hazard function is written as: 
                                                                                                                                     (3.40) 
From the constant baseline hazard function, the corresponding survivor function is: 
      , ∫    
 
 
-   
                                                                                                                  (3.41) 
And so the implied probability density function of the survival times is  
                                                                                                            (3.42)  
This is the probability density function of a random variable T that has an exponential 
distribution with a mean of    .The parameter   with    , is often called the intensity. The 
median event time can be obtained by solving the equation                which leads to 
             . More generally, the  
   quantile can be obtained by solving the equation 
 (  )      and thus         
         
 
                                                             (3.43) 
The main feature of the exponential distribution is thus that the instantaneous hazard does not 
vary over time. Another important property is the lack of memory property. Consider a random 
variable T ∼ Exp ( ). We now study the survival function of a subject conditional on having 
survived up to time         the excess survival time is described by the same exponential 
distribution with constant hazard rate  . An empirical check for this distribution for a set of 
survival data is provided by plotting the log of the survival function estimate versus  . Such a 
plot should resemble a straight line through the origin, as                 if the exponential 
distribution assumption holds. 
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3.8.1.1 Fitting the exponential survival regression model 
In the parametric setting, estimates of the parameters are obtained by maximizing the likelihood 
function. The survival likelihood for survival data with event times and right censored data is 
generally given by: 
  ∏                                                                                                    (3.44) 
which leads for exponentially distributed event times to:  
  ∏                                      
    ∏                                                                                                         (3.45) 
By differentiating the log likelihood function with respect to   and equating this expression to 
zero leads to the maximum likelihood estimator 
  =  
∑        
                                                                                            (3.46) 
3.8.2. The Weibull Survival Regression Model 
The Weibull distribution is a generalization of the exponential distribution. However, unlike the 
exponential distribution, it does not assume a constant hazard rate and therefore has broader 
application. The distribution was proposed by Weibull (1939) and its applicability to various 
failure situations discussed again by Weibull (1951). The baseline hazard function for Weibull 
distributed event times is given by: 
            
                                                                                                                    (3.47) 
It follows that the survival function for the Weibull distribution is given by: 
             
                                                                                               (3.48) 
and the density function is 
           
                                                                                           (3.49) 
with λ,   > 0, the scale parameter and  ,   > 0, the shape parameter.  
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The median event time can be obtained by solving the equation         = 0.5 which leads to 
      (
    
 
)
 
 ⁄
. More the     quantile can be obtained by solving the equation  (  )  
    and thus      (
         
 
)
 
 ⁄
                                                                     (3.50) 
The shape of the hazard function critically depends up on the values of    
If   < 1: hazard decreases monotonically with time 
If   < 1: hazard increases monotonically with time 
If   = 1: constant hazard (equivalent to exponential distribution) 
The Weibull hazard model can be generally presented as 
                                                                                                           (3.51) 
                      
                                                                                           (3.52) 
         
                            
                                                           (3.53) 
with       =    
    and   a p × 1 vector containing the parameters. The event time of the 
     subject is then characterized by the Weibull distribution with scale parameter            
and shape parameter  . Thus, all subjects share the shape parameter but differ with respect to 
their scale parameter. The model assumes that individual i and j with covariates Xi and Xj have 
proportional hazard function of the form: 
  
       
 (    )
    = 
         
   (    )
   =    (  (     ))                                                                        (3.53) 
The quantities        can be interpreted as hazard ratios. 
3.8.2.1 Fitting the Weibull Survival Regression model 
The survival likelihood for Weibull distributed survival data with event times and right censored 
data is generally given by   
    ∏ {(                  )
               
    }                                          (3.54) 
resulting in the log likelihood function 
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                 ∑          ∑   
  
   
 
                                          (3.55) 
with   the total number of events. Maximum likelihood estimators can be obtained by equating 
the first derivatives of   with respect to   and   to zero and we get. 
ˆ  =  
 
∑         
ˆ
  and 
 
 
ˆ
 ∑         
 
∑         
ˆ
 
   ∑   
  
                                                  (3.56) 
which is nonlinear in ˆ and can only be solved by a numerical procedure such as the Newton 
Raphson algorithm. 
3.8.3. Model Selection in Parametric Survival Regression Models  
To select the model that can predict the survival of MDR TB patient, we have two methods. The 
first is graphical approach. For this method the cox-Snell plot is the common one. It is a graph of 
the minus ln of Kaplan-Meier plotted against the cox-Snell residual values. It is used to 
determine how well a specific distribution fits to the observed data. This plot would be 
approximately linear if the specified theoretical distribution is the correct model. Easy fit 
displays the reference diagonal line along which the graph points should fall along with the 
goodness of fit tests; the distribution plots can be helpful to determine the best fitting model. The 
fundamental difference of this approach is that it is quite subjective to come on conclusion while 
the goodness of fit tests are “exact” in the sense that the results do not depend on the researcher  
(provided that the tests are performed correctly), using plot is a more empirical way to use in 
model selection. Akaikie (1974) proposed an informative criterion (AIC) statistic to compare 
different models and/or models with different numbers. For each model the value is computed 
as:  
      𝐴𝐼𝐶=−2log   𝑘   h    +2 ( +1+k)                                                                                  (3.52)  
Where,   denotes the number of covariates in the model without including the constant term and 
k is the number of parameters minus one i.e.  =0 for the Exponential regression and k=1 for 
Weibull regression models. According to the criterion, a model with small AIC value will be 
considered as it fits for the data. 
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CHAPTER FOUR 
4. RESULT AND DISCUSSION 
4.1 Descriptive survival analysis 
4.1.1 Socio-Demographic Characteristics  
The study included 146 MDR TB patients, who had known outcome, with 42 (28.8%) of the 
patients were died and the rest 104 (71.2%) of the patients were censored at the time of the study. 
Table 4.1 shows the total of 146 MDR TB patients, 60.3% were males and 39.7% were females. 
Regarding MDR TB patients‟ age at the time of diagnosis, 36.9% patients were between 18-34 
years old, 37.7 % patients were between 35-54 years old and the remaining 25.4% patients were 
more than 54 years old. When we come to marital status of the MDR TB patient 36.9%, 46.6%, 
10.3% and 6.2% of the patients were Single, Married, Separated/ divorced and Widow/Widowed 
respectively. With regard to educational attainment, about 22.6% of the patients were Illiterate, 
46.6% had only read and write, 28.1% of the MDR TB patients were Secondary and the 
remaining 13.0% were Tertiary and above. There were 13.0% of employed MDR TB patients, 
28.8% were has their own business, 8.9% were Day laborer and most 49.3% of MDR TB 
patients were unemployed. 92.5% of MDR TB patients were orthodox and the proportion of 
protestant and Muslim respectively was 1.3% and 6.2%. 
Table 4.1: Summary of some important socio-demographic characteristics of MDR TB patients 
at Gondar University hospital 
Covariates Category Censored (%)  Event/ Death (%) Total (%) 
Sex of the patient  
Male 63 (71.6) 25 (28.4) 88(60.3) 
Female  41 (70.7) 17 (29.3) 58(39.7) 
Age of the patient  
18-34 years  
35- 54 Years 
>=55 years  
49 (90.7) 
33 (60) 
22 (59.5) 
5 (9.3) 
22 (40) 
15 (40.5) 
54 (36.9) 
55 (37.7) 
37 (25.4) 
Marital status of the 
patient  
Single 45 (83.3) 9 (16.7) 54 (36.9) 
Married 43 (63.2) 25 (36.8) 68 (46.6) 
Separated/ Divorced 10 (66.7) 5 (33.3) 15 (10.3) 
Widow/Widowed 6 (66.7) 3 (33.3) 9 (6.2) 
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Educational label of 
the patient 
Illiterate 
Read and Write 
Secondary 
Tertiary and above 
24 (72.7) 
35 (66) 
32 (78) 
13 (68.4) 
9 (27.3) 
18 (34) 
9 (22) 
6 (31.6) 
33 (22.6) 
53(36.3) 
41 (28.1) 
19 (13.0) 
Employment status 
of the patient  
Employed   
Own Business 
Day laborer  
Unemployed 
14 (73.7) 
27 (64.3) 
9 (69.2) 
54 (75) 
5 (26.3) 
15 (35.7) 
4 (30.8) 
18 (25) 
19 (13.0) 
42 (28.8) 
13 (8.9) 
72 (49.3) 
Religion of the 
patient 
Orthodox 
Muslim 
Protestant 
96 (71.1) 
6 (66.7) 
2 (100) 
39 (28.9) 
3 (33.3) 
0 (0) 
135 (92.5) 
9 (6.2) 
2 (1.3) 
4.1.2 Clinical characteristics  
The results displayed in Table 4.2 regarding to therapeutic delay 37.7 % of MDR TB patients 
have started treatment after one month of diagnosis and the remaining 62.3% have started before 
one month of diagnosis. 47.3 of patients were take only INH and RIF at initiation and most 
52.7% of the patients were taken more than INH and RIF at initiation. With regard to addiction, 
27.4 % were smokers and 72.6% of the patients were nonsmokers. Most 63.7 % of the patients 
were alcohol users and 32.3 % of the patients were not alcohol users. Majority 65.8 % of MDR 
TB patients had no clinical complication and the rest 34.2% were with different clinical 
complication, 8.9 %, 11.7 %, 6.8 % and 6.8 % were with Pneumonia, Pneumothorax, 
Hemoptysis and Cor pulmonal clinical complications respectively. Among the MDR TB 
patients, 80.1% were previously treated and 19.9 % were previously not treated and 13.0 % of 
MDR TB patients were HIV positive and most 87.0 % of MDR TB patients were HIV negative. 
With regard to presence of any chronic disease as co-infection, Majority 77.4 % of MDR TB 
patients had no any chronic disease and the rest 22.6 % were with different chronic diseases, 
12.3 %, 4.1 % and 6.2 % were with Diabetes mellitus, Myocardial infarction and Asthma co-
infections respectively. Majority 76.7% of the patients were smearing positive and the remaining 
23.3 % of the patients were smear negative at the time of diagnosis. 
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Table 4.2: Summary of some important clinical characteristics of MDR TB patients at Gondar 
University hospital 
 
Covariates Category Censored (%) Event/ Death (%) Total 
Therapeutic Delay 
>= 1 month 
< 1 month 
30 (54.5) 
74 (81.3) 
25 (45.5) 
15 (18.7) 
55 (37.7) 
91 (62.3) 
Number of first line 
drugs 
INH and RIF only 
More than INH and RIF 
37 (53.6) 
67 (87) 
32 (46.4) 
10 (13) 
69 (47.3) 
77 (52.7) 
Smoking status 
Yes 
No 
12 (30) 
92 (86.8) 
28 (70) 
14 (13.2) 
40 (27.4) 
106 (72.6) 
Alcohol use 
Yes  
No 
54 (58.1) 
50 (94.3) 
39 (41.9) 
3 (5.7) 
93 (63.7) 
53 (32.3) 
Any clinical 
complication 
No complication 
Pneumonia 
Pneumothorax 
Hemoptysis 
Cor pulmonal 
81 (84.4) 
4 (30.8) 
10 (58.8) 
5 (50) 
4 (40) 
15 (15.6) 
9 (69.2) 
7 (41.2) 
5 (50) 
6 (60 
96 (65.8) 
13 (8.9) 
17 (11.6) 
10 (6.8) 
10 (6.8) 
MDR Category 
Previously Treated 
Previously not Treated 
97 (82.9) 
7 (24.1) 
20 (17.1) 
22 (75.9) 
117 (80.1) 
29 (19.9) 
HIV Co-infection 
Positive  
Negative 
3 (15.8) 
101 (79.5) 
16 (74.2) 
26 (20.5) 
19 (13.0) 
127 (87.0) 
Presence of any 
chronic disease 
No chronic disease 
Diabetes mellitus  
Myocardial infarction 
Asthma 
93 (82.3) 
10 (55.6) 
0 (0) 
1 (11.1) 
20 (17.7) 
8 (44.4) 
6 (100) 
8 (88.9) 
113 (77.4) 
18 (12.3) 
6 (4.1) 
9 (6.2) 
Smear positivity 
Positive 
Negative 
89 (73.6) 
10 (60 
32 (26.4) 
15 (40) 
112 (76.7) 
25 (23.3) 
4.2 Comparison of Kaplan Meier Survival Curves    
The survival status of the total of study subjects 42 (28.7%) were died and 104 (71.3%) were 
censored at August; 2014. The minimum duration of follow up was 1 Month and maximum was 
37 months. Table 1 of Appendix B showed that the probability of time to death was high in the 
first months, which relatively decreases as follow up time increases. During the first month of 
MDR TB treatment, the maximum (97.95%) probability of death  was observed with a standard 
error of 0.0117, at the 6
th
 months the probability of continuing death of  MDR TB patient treated 
with  MDR TB treatment was 88.21% with a standard error of 0.0269, at the 12
th
 months  the 
probability of continuing death of  MDR TB patient treated with  MDR TB treatment was 
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80.35% with a standard error of 0.0333 and at the 24
th
 months the probability of continuing death 
of  MDR TB patient treated with  MDR TB treatment was 69.68% with a standard error of 
0.0394 for the follow-up period of time. In addition, the plot of overall Kaplan-Meier estimate 
indicate that for MDR TB patients who were treated at University of Gondar Hospital, death 
relatively decreases as follow up time increases (see figure 4.1). 
Table 4.3 below shows that the mean duration of MDR TB patients in Gondar University 
Hospital were 28.834 months. The 95% confidence interval of mean duration of MDR TB 
patients treated at university of Gondar hospital lies between 26.712 and 30.956 months. 
Table 4.3: over all mean for survival time of MDR TB patients and their 95%CI & SE. 
Mean 
Estimate Std. error 
95% Confidence Interval 
Lower Bound Upper Bound 
28.834 1.083 26.712 30.956 
 
 
Figure 4.1: Overall product limit estimate of survival function 
 
Table 4.4 shows that the average duration of male MDR TB patients (28.996 months) was higher 
than that of mean duration of (20.924months) of female sex.  The mean duration of time to death 
was 23.753 months for MDR TB patients of younger age-group (18- 34 years old), 25.922 for 
age group of 35-54 years old and 19.070 months for older MDR TB patients. The average 
duration of time to death was higher in married (26.873 months) MDR TB patients and lower in 
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Widow/Widowed (18.667 months) MDR TB patients. The mean duration of time to death of 
single and divorced MDR TB patients were 23.459 months and 20.333 months respectively. 
Relatively the average duration of time to death of MDR TB patients was higher in patients who 
started treatment before one month after diagnosis (31.775 months) than who started treatment 
after one month of diagnosis (17.634 months). The mean duration of time to death of MDR TB 
patients was 33.408 months for patients who took more than INH and RIF and 17.547 months for 
patients who took only INH and RIF. Generally the average duration of time to death due to 
MDR TB was lower in non-addicted patients than addicted patients. The highest mean duration 
of time to death was 32.351 months for patients, who had no any clinical complication, 14.385 
months for patients who had Pneumonia complication, 18.971 months for patients who had 
Pneumothorax complication, 18.800 months for patients who had Hemoptysis complication and 
14.300 months for patients who had Cor pulmonal complication. The mean duration of time to 
death of HIV positive MDR TB patients was 11.147 months and HIV negative MDR TB patients 
was 31.216 months. The average duration of time to death was higher in non-chronic co-infected 
(32.004 months) MDR TB patients and lower in Myocardial infarction co-infected (8.333 
months) MDR TB patients. The mean duration of time to death of Diabetes mellitus co-infected 
and Asthma MDR TB patients were 16.944 months and 12.778 months respectively. 
Table 4.4:  mean duration for survival time of MDR TB patients and their 95%CI & SE by 
different socio-demographic and clinical characteristics based on Kaplan-Meier technique 
Covariates Category 
Mean duration 
of  the patient 
95% Confidence interval 
 
Lower bound Upper bound 
Sex of the 
patient  
Male 28.996 26.292 31.700 
Female  20.924 18.775 23.072 
Age of the 
patient  
18-34 years  
35- 54 Years 
>=55 years  
23.753 
25.922 
19.070 
22.647 
22.230 
15.861 
24.859 
29.613 
22.273 
Marital status of 
the patient  
Single 23.459 21.283 25.636 
Married 26.873 23.654 30.092 
Separated/ Divorced 20.333 17.216 23.451 
Widow/Widowed 18.667 13.541 23.793 
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Educational 
label of the 
patient 
Illiterate 
Read and Write 
Secondary 
Tertiary and above 
22.042 
19.764 
30.656 
19.425 
19.067 
17.662 
26.934 
16.003 
25.016 
21.865 
34.375 
22.847 
Employment 
status of the 
patient  
Employed   
Own Business 
Day laborer  
Unemployed 
30.195 
19.375 
19.923 
21.650 
25.000 
17.347 
14.125 
19.753 
35.391 
21.367 
25.721 
23.547 
Therapeutic 
Delay 
>= 1 month 
< 1 month 
17.634 
31.775 
15.290 19.978 
29.502 34.047 
Number of first 
line drugs 
INH and RIF only 
More than INH and RIF 
17.547 
33.408 
15.488 
31.282 
19.606 
35.533 
Smoking status 
Yes 
No 
14.360 
33.084 
11.851 
31.152 
16.869 
35.015 
Alcohol use 
Yes  
No 
25.178 
25.846 
22.289 
24.574 
28.067 
27.118 
Any clinical 
complication 
No complication 
Pneumonia 
Pneumothorax 
Hemoptysis 
Cor pulmonal 
32.351 
14.385 
18.971 
18.800 
14.300 
30.169 
9.125 
15.531 
14.921 
8.525 
34.533 
19.644 
22.410 
22.679 
20.075 
MDR Category 
Previously Treated 
Previously not Treated 
32.174 
12.931 
30.210 
10.059 
34.137 
15.803 
HIV Co-
infection 
Positive  
Negative 
11.147 
31.216 
7.981 
29.197 
14.314 
33.236 
Presence of any 
chronic disease 
No chronic disease 
Diabetes mellitus  
Myocardial infraction 
Asthma 
32.004 
16.944 
8.333 
12.778 
29.983 
12.954 
4.876 
7.823 
34.024 
20.935 
11.790 
17.732 
Smear positivity 
Positive 
Negative 
29.337 
18.720 
27.021 
15.963 
31.653 
21.477 
 
Separate graphs of the estimates of the Kaplan-Meier  functions for all covariates  are presented  
in  Figures 1C  Appendix(C)  in  order  to  see  whether  there  is difference  in  time to death 
between  different categories of  individuals. The Log-rank test was performed to investigate the 
significance of the observed difference in the Kaplan-Meier estimates of the survivor functions 
among different categories of the covariates. The Kaplan-Meier graphs for a covariate crossing 
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more than one times indicating that the variable is insignificant. All of the graphs show 
differences between different categories except sex of the patient, marital status of the patient, 
educational label of the patient, employment status of the patient, religion of the patient and 
smear positivity. The upper curve in each Figure indicates that the particular group experiences 
more survival time than the one below. In  order  to  investigate  if  there  is significant difference  
between  the time of death of  MDR TB  patients  by  sex,  Kaplan-Meier  survivor  estimates  for  
the  two  gender  groups  are  plotted in  appendix C. This Figure shows that males had more 
survival time as compared to females. Similar  analysis  is  performed  to  investigate  differences 
in  the time to death among  the patients  with  respect  to marital status, educational  level, 
employed status, religion and smear positivity from the Kaplan-Meier curves in Appendix C 
shows  that  the  curves  cross  each  other  more  than  one times indicating  that  there  is  no 
difference between  time to death of these group patients. The result from Table 4.5 the p-value 
of the Log-rank test pointed out that all factors except sex of the patient, marital status of the 
patient, educational label of the patient, employment status of the patient, religion of the patient 
and smear positivity have differences in the survival experiences among their categories at 5% 
level of significance.  
Table 4.5: Results of log-rank test of equality of survival distribution for the different 
categorical covariates  
Covariates/Factors  Chi-square Df p-value 
Sex of the patient 0.027 1 0.870 
Age of the patient 15.231 2 0.000 
Marital status of the patient 4.813 3 0.186 
Educational label of the patient 1.555 3 0.670 
Employment status of the patient 1.590 4 0.811 
Religion of the patient 0.741 2 0.690 
Therapeutic Delay 12.253 1 0.000 
Number of first line drugs 21.260 1 0.000 
Smoking status 48.971 1 0.000 
Alcohol use 20.232 1 0.000 
Any clinical complication 29.320 4 0.000 
 MDR Category 48.555 1 0.000 
HIV Co-infection 50.166 1 0.000 
Presence of any chronic disease 55.603 3 0.000 
Smear positivity 1.272 1 0.259 
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+4.3 Cox Proportional Hazard Regression Model  
4.3.1 Univar ate Cox proportional hazards model    
After making a comparison of the survivorship experience among groups of covariates, the next 
important step is model development. An initial step in the model building process is to identify 
sets of explanatory variables that have the potential for being included in the linear components 
of a multivariable proportional hazards model. We started with fitting univariable Cox 
proportional hazards regression model. Table 2B (Appendix B) shows that fifteen univariable 
Cox proportional hazards models were fitted. 
The result from Table 2B (Appendix B) shows that not all explanatory variables are important to 
fit multi-covariate Cox proportional hazards model. Thus, the important covariates were selected 
based on their contribution to the maximized log partial likelihood of the model (-    ( ̂)). The 
value of -    ( ̂) for the null model is 401.960. Therefore, inclusions of covariates were based 
on the amount of reduction of this value and p-value. The bigger the reduction of this value, the 
better fit. Hence, based on the amount of reduction the log partial likelihood of variable smoking 
status has high contribution to maximized log partial likelihood of the model (-    ( ̂) ) 
because it shows highest reduction in (-    ( ̂)). It reduces the value from 401.960 to 363.796. 
This reduction of 38.164 is highly significant (p-value < 0.0001) when compared with 
percentage points of the distribution on 1 degree of freedom. The second highest reduction in (-
    ( ̂)) is obtained from variable MDR category and it shows significant change. It reduces 
the value from 401.960 to 368.893, which reduced the statistic by 33.067. Then, the reduction in 
(-    ( ̂)) due to the inclusion of chronic co-infection, HIV co-infection, alcohol intake,  any 
clinical complication, number of drugs at initiation, age of the patient and therapeutic delay to 
the null model successively one at a time are 32.371, 29.007, 24.961, 23.604, 21.081, 17.621, 
11.298 respectively. All of them are significant using the chi-square test (Wald test) at 5% level 
of significance. But the reduction in (-     ( ̂) ) due to the inclusion of marital status, 
educational label, religion of the patient, smear positivity, employment status and sex of the 
patient to the null model successively one at a time are 5.111, 1.567, 1.441, 1.15, 1.147  and 
0.026 respectively and they are not significant at 5% level of significance. Hence all these 
covariates except marital status, educational label, religion of the patient, smear positivity, 
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employment status and sex of the patient are considered in the multivariable Cox regression 
model. The results are shown in table 3 of Appendix B. We then applied stepwise variable 
selection method (Collett, 2003) to obtain the reduced model. 
At the next step of fitting the Cox proportional hazard model using the variables in Table 3B 
(Appendix B) and the value of (-    ( ̂)) will be 285.062. Then, omitting variables from the 
model will be based on the increasing in (-    ( ̂)) and p-value. The variable smoking status of 
the patient did not have significant increment and the p-value is 0.081. Therefore, the variable 
smoking status of the patient is excluded from the model and hence the reduced model consisted 
of the remaining six variables. Table 4.6 shows the fitted reduced model. 
The final step in model development strategy is the consideration of interaction terms that may 
be useful in the improvement of the model. An interaction term is a new variable that is the 
product of two other variables in the reduced model. Note that there can be subject matter 
considerations that dictate that a particular interaction term (or terms) should be included in a 
given model, regardless of their statistical significance. In most settings there is no biological or 
clinical theory to justify automatic inclusion of interactions. The significance of each separate 
interaction is assessed by adding interaction terms to the main effects model one at a time and 
using the Wald test. All significant interactions should be included in the main-effects model. 
Then, examining the p-values of the Wald statistic in Table 4B (Appendix B) shows that there 
are no significant interaction effects at 5% level of significance. 
Hence, our preliminary final model contains only the main effects of Therapeutic Delay, Number 
of drugs at initiation, Alcohol intake, any clinical complication, HIV co-infection and chronic co-
infection. The following table shows the final model obtained from SPSS. But the interpretation 
based on this model should not be made until the adequacy of the proportional hazards Cox 
regression model has been checked.  
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Table 4.6: the Preliminary Final Model with parameter estimates and hazard ratios of the 
covariates  
 Covariates  B SE Wald X
2
 Df Sig. Exp(B) 
95% CI for Exp(B 
Lower  upper 
DELAY(>=1 month) -1.265 0.425 8.874 1 0.003 0.282 0.123 0.649 
NODRUG (INH &RIF only) -1.434 0.414 12.026 1 0.001 0.238 0.106 0.536 
Alcoholuse (Yes) -1.570 0.629 6.241 1 0.012 0.208 0.061 0.713 
(No Complication) 
Pneumonia 
Pneumothorax 
Hemoptysis 
Cor pulmonal 
 
1.006 
0.035 
0.637 
1.726 
 
0.518 
0.525 
0.584 
0.568 
10.234 
3.769 
0.005 
1.188 
9.233 
4 
1 
1 
1 
1 
0.037 
0.052 
0.946 
0.276 
0.002 
 
2.734 
1.036 
1.891 
5.615 
  
0.990 7.548 
0.370 2.897 
0.601 5.946 
1.845 17.090 
HIV (Positive) -1.488 0.385 14.939 1 0.000 0.226 0.106 0.480 
Chronic (no chronic) 
Diabetes mellitus 
Myocardial infraction 
Asthma 
  24.405 
6.479 
16.566 
12.862 
3 
1 
1 
1 
0.000 
0.011 
0.000 
0.004 
 
 
 
1.343 
3.492 
2.161 
 
 
9.691 
35.626 
13.841 
1.283 
2.412 
1.699 
0.504 
0.593 
0.474 
3.608 
11.153 
5.469 
The reference categories are those indicated in brackets 
4.4 Model Adequacy    
The adequacy of the model needs to be assessed after the model has been fitted to the observed 
survival data. At this point we have a preliminary fitted model and the next step is assessing the 
adequacy of the fitted model should be done in order to evaluate how well the fitted regression 
describes the data set. We started here first by checking the overall goodness of fit using R-
square and LR, Score and Wald tests. We then proceed to check the proportionality assumption 
for each covariate included in the final model. 
4.4.1 Overall Goodness of Fit 
A perfectly adequate model may have low R
2
 due to high percent of censored data. The value of 
the -2Log-Likelihood of the model with covariates in table 4.5 which is equal to 308.894 and the 
-2Log-Likelihood for the null or empty model equals 401.960. The measure of goodness of fit 
R
2
p is calculated as:   
  =1- exp[
 
 
(LO - Lp)] = 1-exp[
 
   
((-200.98-(154.4470))] = 0.4713. Results 
of the Likelihood Ratio, Score and Wald tests for model goodness of fit displayed in Table 4.7 
also suggests that model is good fit, i.e. significant at 5% level of significance. 
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Table 4.7: The Likelihood Ratio, Score and Wald tests for overall measures of goodness of fit of 
the preliminary final model in table 5A  
Test     Chi-Square      Df             Pr > Chisq 
Likelihood Ratio 93.0666         6 <.0001 
Score 116.7047         6 <.0001 
Wald 73.4573         6 <.0001 
Testing Global Null Hypothesis: BETA=0 
4.4.2 Testing the Proportional Hazards Assumption 
There are two basic assumptions of the Cox Regression model. The first one is log-linearity, that 
is, the relationship between log hazard or log cumulative hazard and a covariate is linear. Since 
all covariates used in the final model are categorical, there is no need of checking linearity. The 
second one is proportional hazards (the time independence of the covariates in the hazard 
function, that is, the ratio of the hazard function for two individuals with different regression 
covariates does not vary with time). A proportional hazard is one of the very important 
assumptions in the Cox model.  
The adequacy of the preliminary final model is checked for the validity of proportional hazards 
assumption using test based on the interaction between variables in the model with logarithm of 
survival time and assess their significance using the Wald test. Also the plot of the scaled 
schoenfeld residuals is used to provide any additional insight into any departure from 
proportionality. Under the assumption of proportionality of the proportional hazards model, the 
distribution of residuals over time is random and lowess smoothing line should be a straight line 
around zero, with no particular trend with time. Table 4.8 below shows the SAS output for 
testing proportionality assumption. 
From Table 4.8 we can see the Wald chi-square values and the corresponding p-values for each 
covariate. Since the p-values for each interaction of covariate with logarithm of time are greater 
than 0.05, the proportionality assumption is satisfied. The global fit test also shows that the Wald 
chi-square test statistic is not significant which indicates that the proportional hazards 
assumption is not violated. Appendix C (Figures 1C to Figures 6C) shows the plots of the scaled 
Schoenfeld residuals for each covariate against time. The plot of the scaled schoenfeld   
Appendix C shows that the residuals are random without any systematic pattern and the 
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smoothed plot looks straight line without any departure from the horizontal line. Thus, there is 
no violation of proportional hazards assumption. 
Table 4.8: Result of test of proportionality assumption for each covariate in the final model 
Analysis of Maximum Likelihood Estimates 
Variable DF Parameter 
Estimate 
Standard Error 
 
Chi-Square  Pr > ChiSq Hazard 
Ratio 
DELAY 1 -1.06222 0.88614 1.4369 0.2306 0.346 
NODRUG 1 -0.73675 0.91332 0.6507 0.4199 0.479 
Alcoholuse 1 -1.00006 1.38314 0.5228 0.4697 0.368 
Clnccomplicn 1 0.13676 0.28632 0.2282          0.6329 1.147 
HIV 1 -0.59229 0.89481 0.4381          0.5080 0.553 
CHRONIC 1 0.17826 0.34485 0.2672 0.6052 1.195 
DELAYT 1 -0.21720 0.42376 0.2627          0.6083 0.805 
NODRUGT 1 -0.27990 0.41979 0.4446          0.5049 0.756 
AlcoholuseT 1 -0.28596 0.64064 0.1992          0.6553 0.751 
ClnccomplicnT 1 0.04935  0.13591 0.1319          0.7165 1.051 
HIVT 1 -0.43167  0.43439 0.9875          0.3204 0.649 
CHRONICT   1    0.15722    0.16481     0.9100   0.3401 1.170 
Linear Hypotheses Testing Results 
                         Label Wald  Chi-Square DF Pr > ChiSq 
                       test_proportionality 4.3879    6 0.6243 
 
4.5 Interpretation and discussion of the results  
The study assessed survival of MDR TB patients and examined the socio-demographic and 
clinical determinants of MDR TB patients in Gondar university hospital. In survival analysis the 
measure of effect is the hazard ratio. It is interpreted in the same way as the odds ratio. The 
higher the hazard ratio the lower is the survival probability, and vice versa. If for an exposed 
group the hazard ratio is high, the survival probability would be equivalently low. From the final 
model in Table 4.6 we obtained six significant main effects:  Therapeutic delay, number of drugs 
at initiation, alcohol intake, any clinical complication, HIV co-infection and chronic co-infection 
of the patients. 
Therapeutic delay has a significant negative association with mortality of MDR TB patients. 
After adjusting other covariates, the estimated coefficient is -1.265 for a confirmed MDR-TB 
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patient who starts treatment before one month and the hazard ratio is 0.282. This indicates that 
the hazard of death  of MDR TB patients is reduced  by 71.8 % for a confirmed MDR TB patient 
who starts treatment before one month relative to a confirmed MDR TB patients who started 
treatment after one month (adjusted HR=0.282, 95% CI=0.123-0.649). The 95% confidence 
intervals also suggest that the rates could be as low as 0.123 and as high as 0.649. that means the 
risk of death  of MDR TB patients who starts MDR treatment before one month could be as low 
as 0.123 and as high as 0.649. This finding is consistent with Theodros Getachew et al. (2013). 
The result of this study revealed that a negative relationship between number of drugs taken at 
initiation and duration of MDR TB patients. After adjusting for other covariates, the estimated 
coefficient is -1.434 for MDR TB patients who took more than INH and RIF at initiation and the 
hazard ratio is 0.238. This indicates that the hazard of death  of MDR TB patients is reduced  by 
76.2 % for a confirmed MDR TB patient who took more than INH and RIF at initiation relative 
to a confirmed MDR TB patients who takes INH and RIF only  (adjusted HR=0.238, 95% 
CI=0.106-0.536). The study revealed that the risk of death of MDR TB patients who takes more 
than INH and RIF drugs at initiation is lower than patients who take only two drugs (INH and 
RIF only) at initiation.   
The hazard ratio of MDR TB patients who are not using alcohol as compared to those who use 
alcohol is 0.208. This means the risk of death for MDR TB patients who are not using alcohol is 
about 0.208 times higher than MDR TB patients who are used alcohol. The 95 % confidence 
interval also suggests that the risk of death for MDR TB patient who are not used alcohol is 
0.061 times as low and 0.713 times as large as those who are used alcohol drink. Alcohol use is 
negatively related with MDR TB patient‟s survival chances. A similar trend that MDR-TB 
subjects have an overall lower lifetime prevalence of any alcohol use than the non-alcohol user 
was also observed in some other study in Botswana Zetola N. et al. (2012). 
After adjusting for other covariates, the hazard of death of MDR TB patients with Pneumonia 
complication is 2.734 times higher than MDR TB patients who have no any clinical complication 
(adjusted HR=2.734, 95% CI: 0.990, 7.548). The hazard of death of MDR TB patients with 
Pneumothorax complication is 1.036 times higher than MDR TB patients who have no any 
clinical complication (adjusted HR=1.036,  95% CI: 0.370, 2.897). The hazard of death of MDR 
TB patients with Hemoptysis complication is 1.891 times higher than MDR TB patients who 
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have no any clinical complication ((adjusted HR=1.891,  95% CI: 0.601, 5.946). The hazard of 
death of MDR TB patients with Cor pulmonal complication is 5.615 times higher than MDR TB 
patients who have no any clinical complication (adjusted HR=5.615, 95% CI: 1.845, 17.090). All 
these hazard ratios indicate that the risk of death of MDR TB patients with different clinical 
complication is higher than relative to MDR TB patients with no clinical complication.  
The estimated relative risk (hazard ratio) of time to death for MDR TB patients who are HIV 
negative as compared to HIV positive patient is 0.226 (95% CI: 0.106-0.480). This indicates that 
the hazard of death of MDR TB patients is reduced by 77.4 % for confirmed MDR TB patients 
who are HIV negative relative to a confirmed MDR TB patients who are HIV positive. The 95% 
confidence interval also suggests that the risk of death for HIV negative MDR TB patients could 
be as low as 0.106 and as high as 0.480.  Hence, HIV co-infected MDR TB patients have a 
relatively-shorter duration than HIV negative MDR TB patients. This finding is consistent with 
Yanina Balabanova et al. (2011) and Samuel OM Manda et al. (2004). 
After adjusting other covariates, the hazard of death of MDR-TB patients with Diabetes mellitus 
co-infection is 3.608 times higher than MDR-TB patients who have no chronic co-infection 
(adjusted HR=3.608, 95% CI: 1.343, 9.691). The hazard of death of MDR-TB patients with 
myocardial infarction co-infection is 11.153 times higher than MDR TB patients who have no 
chronic co-infection (adjusted HR=11.153, 95% CI: 3.492, 35.626). The hazard of death of 
MDR- TB patients with Asthma co-infection is 5.469 times higher than MDR-TB patients who 
have no chronic co-infection (adjusted HR=5.469, 95% CI: 2.161, 13.841). These all hazard 
ratios indicate that the risk of death of MDR-TB patients with different chronic co-infection is 
higher than relative to MDR-TB patients with no chronic co-infection. This finding is consistent 
with Matthew J. Magee et al. (2014) and Kang YA et al. (2013) 
4.6. Parametric Regression Modelling of Survival Time of MDR TB Patients 
4.6.1. Model Selection for Survival Time of MDR TB Patients 
For the survival of MDR tuberculosis patients the parametric regression models were fitted. We 
consider model comparison after adjusting for the effect of covariates. In this case the graphical 
displays are based on the Cox-Snell plots. That is, if the model is good, the plot of Cox-Snell 
residuals versus Nelson-Aalen cumulative hazard estimates should lie along the 45 degree 
diagonal line that passes through the origin. Using all the covariates in the study, we fitted two 
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parametric regression models the Exponential and Weibull models with the corresponding AIC 
and BIC values. Here we present the Cox-Snell plots for model comparison in Figures 4.2 to 4.3. 
 
 
                                                                                                         
                                                                                                                                                 
  
From the Cox-Snell plots in Figures 4.2 and 4.3, it is observed that Weibull regression model 
seems the best fit among the two models. But graphical methods may not assure the result. The 
common applicable criterion to select the model is the Akaikie information criterion (AIC) 
statistic proposed by Akaikie (1974). So, In addition to the graphical comparison of the three 
parametric regression models, I used Akaikie information criterion (AIC) and Bayesian 
information criterion (BIC) to choose the best model out of the four possible models.  The 
STATA output of the two parametric survival regression models are displayed in appendix B 
from table 5 to table 6 with the corresponding AIC and BIC values.  
Table 4.9: Statistics for model comparison 
Model Observation ll (null) Ll (model) AIC value BIC value DF 
Exponential 146 -132.3478     -77.32542      186.6508     234.3886 16 
Weibull 146 -132.345    -72.65042      179.3008     230.0222 17 
According to the results in Table 4.9, the Weibull regression model with the smallest value of 
AIC and BIC seems to be the best fit of the two models. Nevertheless, the results of cox-snell 
were consistent with the results based on Akaikie‟s information criterion. Thus, the Weibull 
regression model is considered further to discuss the effect of covariates on the survival of MDR 
TB patients. 
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4.6.2 Univariate unadjusted Weibull regression model 
As Weibull regression is selected, According to the Weibull analysis of single covariate, the 
selected risk factors for further analysis and interpretation are made here below. To have an idea 
about the individual effects of the different explanatory variables on survival of MDR TB 
patients, we fitted Weibull regression model separately for each explanatory covariate. The 
results are shown in Table 4.10 bellow. 
Table 4.10.The result of un-adjusted univariate analysis using Weibull regression model 
covariate Estimate Std.error Chi-
square 
p-value Df -2*LL 95% CI 
Lower Upper 
Sex 0.0549 0.3178 0.03 0.8628 1 264.6605 -0.5680 0.6779 
Age -0.6862 0.2177 9.94 0.0016 2 252.1908 -1.1129 -0.2595 
MRSUS -0.2634 0.1739 2.30 0.1297 3 262.427 -0.6042 0.0773 
EDULABL 0.0488 0.1615 0.09 0.7627 3 264.598 -0.2678 0.3653 
EMPSUS 0.0157 0.1051 0.02 0.8809 4 264.667 -0.1902 0.2217 
Religion 0.2978 0.5298 0.32 0.5740 2 264.327 -0.7405 1.3361 
DELAY 1.0588 0.3389 9.76 0.0018 1 252.809 0.3945 1.7231 
NODRUG 1.4989 0.3873 14.97 0.0001 1 241.482 0.7397 2.2580 
Smokstatus 1.8698 0.3771 24.58 <0.0001 1 223.345 1.1307 2.6090 
Alcoholuse 2.1721 0.6565 10.95 0.0009 1 239.364 0.8853 3.4589 
Clnccomplicn -0.3829 0.1092 12.29 0.0005 4 251.054 -0.5970 -0.1688 
MDRCAT -1.7724 0.3515 25.42 <0.0001 1 229.927 -2.4614 -1.0834 
HIV 1.8464 0.3429 28.99 <0.0001 1 232.998 1.1742 2.5185 
CHRONIC -0.7030 0.1398 25.28 <0.0001 3 235.643 -0.9771 -0.4290 
SMEAR -0.4034 0.3702 1.19 0.2759 1 263.560 -1.1289 0.3222 
 
Results displayed in Table 4.10, illustrate that the statistically significant risk factors for the 
survival probability of multidrug resistant tuberculosis patients are Age of the patient, 
Therapeutic delay, Number of first line drugs at initiation, Smoking status, Alcohol use, any 
clinical complication, MDR category, HIV co-infection and chronic co-infection. Whereas the 
risk factors that were not statistically significant are sex of the patient, marital status, educational 
label of the patient, employment status, religion of the patient and smear positivity at 5% level of 
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significance. The risk factors those were statistically significant included in the final Weibull 
regression model for the prediction of survival probability of MDR TB patients. 
4.6.3 Multivariable Analysis Weibull regression model 
When there are a number of explanatory variables of possible relevance, the effect of each term 
cannot be studied independently of the others. The effect of any given term therefore depends on 
the other terms currently included in the model. However, in the univariate analysis technique 
the relations that are obtained for one factor do not take into account the other factors. So the 
multivariable analysis is used to know the most important factors associated with mortality of 
MDR TB patients in relation to the covariates included in the model. After fitting the univariate 
weibull survival regression analysis the next step is selecting the most important variables to fit 
the multivariate weibull regression model. In order to select the most important covariates in the 
final model, we used stepwise variable selection. The results of the stepwise selection are 
displayed in table 8 of appendix B. 
Results presented in Table 4.11 indicate the parameter estimates of coefficients for the covariates 
in the final Weibull regression model along with the associated significance level, hazard ratio 
with corresponding standard error and 95% confidence interval for the hazard ratio. Survival 
time of MDR TB patients were significantly related with age of the patient, therapeutic delay, 
number of drugs at initiation, alcohol use, any clinical complication, MDR category, HIV co-
infection and chronic co-infection as can be seen from the Table 4.11 bellow. 
Table 4.11.Summary of parameter estimates of the final multivariate weibull model 
 
Covariates 
             
Coef.    
 
          
Std. Err.       
             
z 
 
P>|z|      
 
Haz. Ratio    
 
[95% Conf. Interval] for 
Haz. Ratio 
Lower Upper 
Age (18-34 years) 
35-54 years 
>=55 years 
       
1.050358    
1.460258    
1.584558      
2.513778      
1.89    
2.50 
0.058 
0.012 
2.858673    
4.307071    
0.9645951     
1.372104   
8.471963 
13.52001 
DELAY (>=month) -1.382157    0.1070241     -3.24    0.001      0.2510366    0.1088542     0.5789337 
NODRUG (INH &RIF 
only) 
-1.288478    0.1144644     -3.10    0.002      0.27569    0.1221824     0.6220619 
Alcoholuse (Yes) -1.441549    0.1481942     -2.30    0.021      0.236561    0.0692957     0.8075703 
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Clnccomplicn (No) 
Pneumonia 
Pneumothorax 
Hemoptysis 
Cor pulmonal 
       
0.418614     
0.292495    
0.292495 
1.700102    
0.861957      
0.758625 
0.794574      
3.187495      
0.74    
0.66    
0.49    
2.92    
0.460      
0.509      
0.622      
0.004      
1.519854    
1.422056    
1.339767    
5.474506    
0.5001017     
0.4998341     
0.4189941     
1.748793     
4.618974 
4.045831 
4.284011 
17.13766 
MDRCAT (Previously 
treat ) 
0.7966434    0.9148459      1.93    0.053      2.218083    .9883271     4.978001 
HIV (Positive) -1.277784    0.1155582     -3.08    0.002       0.278654    0.123615     0.6281446 
Chronic (no chronic) 
Diabetes mellitus 
Myocardial infraction 
Asthma 
       
1.209424    
1.796817    
1.689863    
1.792501      
3.892995      
2.677192      
2.26    
2.78    
3.42    
0.024      
0.005      
0.001      
3.351552    
6.030419    
5.418741    
1.174898     
1.701556     
2.057559     
9.560745 
21.37218 
14.27067 
ln_p 0.4955398    0.1329137      3.73    0.000      0.4955398    0.2350337     0.7560459 
P 1.641384    0.2181624                       1.641384    1.264951     2.129838 
1/p 0.6092419    0.0809766                       .6092419    .4695193     .7905442 
The reference categories are those indicated in brackets. 
4.6. 4 Assessment of Adequacy of the Weibull Regression Model 
 The likelihood ratio test presented in Table 4.12, it illustrate that the model was significantly fit 
the data of MDR TB patients and in using the log likelihood values of the null model and the full 
model, it can be seen that the model has a significant improvement after the covariate is 
incorporated in the model.  
Table 4.12 The likelihood ratio and significance of the Weibull regression model 
 
Log likelihood 
(intercept only) 
Log likelihood  
(Model) 
LR chi-
square 
DF Prob > chi2 Intercept Scale 
-132.34495 -75.385077 113.92 8 0.0000 -4.114011 1.529221 
 
4.6.5. Interpretation and Discussion of the Weibull Regression Model 
From the Weibull regression model, age of the patients is positively associated with mortality of 
MDR TB patients. After adjusting the other covariates, the hazard rate of MDR TB patients who 
had age group 35 -54 years was 2.858673 times than of MDR TB patients who had age group 
67 
 
18-34 years (adjusted HR=2.858673,95% CI=0.9645951,8.471963). The hazard rate of MDR-TB 
patients who had age group are >=55 years was 4.307071 times than of MDR TB patients who 
had age group 18-34 years (adjusted HR=4.307071,95% CI=1.372104 , 13.52001). Generally the 
finding of this study revealed that an increase of age of the patients declines the survival 
probability of MDR-TB patients. Some other studies showed that age is not a significant factor 
for mortality of MDR-TB patients Getachew et al. (2013) and Ahmed M. Salih et al.  (2010)   
For therapeutic delay, the study revealed that therapeutic delay is a negative significant factor for 
mortality of MDR-TB patients and the hazard rate of MDR TB patients who started treatment 
before one month delay after diagnosis is 0.2510366 times that of MDR-TB patients started 
treatment after one month of diagnosis (adjusted HR = 0.2510366, 95% CI: 0.1088542, 
0.5789337). This indicates that the risk of death of MDR-TB patients who started treatment 
before one month delay after diagnosis is declined by 74.9%.  Adjusting the other covariates, the 
hazard rate of MDR-TB patients who have taken more than INH and RIF drugs at initiation is 
0.27569   times than MDR-TB patients who have taken only INH and RIF at initiation (adjusted 
HR = 0.27569  , 95% CI: 0.1221824 , 0.6220619). This result indicates that the probability of 
survival of MDR-TB patients who had taken more than INH and RIF drugs at initiation is higher 
than relative to MDR-TB patients who had taken only INH and RIF drugs at initiation. Number 
of drugs taken at initiation is negatively significant risk factor for mortality of MDR-TB patients 
at Gondar university hospital. These results confirm the result obtained from the previous studies 
(Theodros Getachew et al. (2013)).   
 
The addiction of alcohol is another prognostic factor that significantly predicts the mortality of 
MDR-TB patients. The result obtained from this study indicates that the hazard ratio of non- 
alcohol takers is 0.236561 times that of alcohol takers (adjusted HR = 0.236561, 95% CI: 
0.0692957, 0.8075703). There is a significantly negative relationship between alcohol use and 
mortality of MDR-TB patients. This result confirms that MDR-TB subjects have an overall 
lower lifetime prevalence of any alcohol use than the non -alcohol user N. M. Zetola et al. 
(2012). 
After adjusting other covariates, the hazard of death of MDR-TB patients with Pneumonia 
complication is 1.519854 times higher than MDR-TB patients who have no any clinical 
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complication (adjusted HR=1.519854 , 95% CI: 0.5001017,4.618974). This result revealed that 
the risk of death of MDR TB patients with Pneumonia complication is 51.9% higher than that of 
MDR TB patients have no any clinical complications. The hazard of death of MDR-TB patients 
with Pneumothorax complication is 1.422056   times higher than MDR-TB patients who have no 
any clinical complication (adjusted HR=1.422056, 95% CI: 0.4998341, 4.045831). This result 
indicates that the risk of death of MDR-TB patients with Pneumothorax complication is 42.2% 
higher than that of MDR-TB patients have no any clinical complications. The hazard of death of 
MDR-TB patients with Hemoptysis complication is 1.339767   times higher than that of MDR- 
TB patients who have no any clinical complication ((adjusted HR=1.339767,95% CI: 0.4189941 
, 4.284011). This result revealed that the risk of death of MDR-TB patients with Hemoptysis 
complication is 33.9% higher than that of MDR-TB patients have no any clinical complications. 
The hazard of death of MDR-TB patients with Cor pulmonal complication is 5.474506 times 
higher than MDR TB patients who have no any clinical complication (adjusted HR=5.474506 , 
95% CI: 1.748793, 17.13766). These all hazard ratios indicate that the risk of death of MDR-TB 
patients with different clinical complication is higher than relative to MDR-TB patients with no 
clinical complication.  
The estimated relative risk (hazard ratio) of time to death for MDR-TB patients who are 
previously not treated as compared to previously treated MDR-TB patients is 2.218083  (95% 
CI: 0.9883271, 4.978001). This indicates that the hazard of death of MDR TB patients is higher 
for confirmed MDR-TB patients who are previously not treated relative to a confirmed MDR-TB 
patient who are previously treated. The 95% confidence interval also suggests that the risk of 
death for previously not treated MDR-TB patients could be as low as 0.9883271and as high as 
4.978001.  Hence, MDR-TB patients who are previously not treated have a relatively-shorter 
duration than previously treated MDR-TB patients. This finding is consistent with E.E Telzak et 
al. (1998) and Songhua Chen et al. (2013). 
The estimated relative risk (hazard ratio) of time to death for MDR-TB patients who are HIV 
negative as compared to HIV positive patient is 0.278654  (95% CI: 0.123615, 0.6281446). This 
indicates that the hazard of death of MDR-TB patients is reduced by 62.2 % for confirmed 
MDR-TB patients who are HIV negative relative to a confirmed MDR-TB patients who are HIV 
positive. The 95% confidence interval also suggests that the risk of death for HIV negative 
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MDR-TB patients could be as low as 0.123615 and as high as 0.6281446.  Hence, HIV co-
infected MDR-TB patients have a relatively-shorter duration than HIV negative MDR-TB 
patients. This finding is consistent with Yanina Balabanova et al. (2011) and Samuel OM Manda 
et al. (2004). 
After adjusting other covariates, the hazard of death of MDR-TB patients with Diabetes mellitus 
co-infection is 3.351552   times higher than MDR-TB patients who have no chronic co-infection 
(adjusted HR=3.351552, 95% CI: 1.174898 ,9.560745). The hazard of death of MDR-TB 
patients with myocardial infarction co-infection is 6.030419  times higher than MDR-TB patients 
who have no chronic co-infection (adjusted HR=6.030419   ,95% CI: 1.701556 , 21.37218). The 
hazard of death of MDR-TB patients with Asthma co-infection is 5.418741 times higher than 
MDR-TB patients who have no chronic co-infection (adjusted HR=5.418741, 95% CI: 2.057559, 
14.27067). These all hazard ratios indicate that the risk of death of MDR-TB patients with 
different chronic co-infection is higher than relative to MDR-TB patients with no chronic co-
infection. This finding is consistent with Matthew J. Magee et al. (2014) and Kang YA et al. 
(2013). 
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CHAPTER FIVE 
5.  CONCLUSION AND RECOMMENDATION 
5.1 Conclusion 
 This study was aimed to identify the survival and predictors of mortality among patients 
under Multi-Drug Resistant Tuberculosis treatment at Gondar University teaching 
Hospital. Fifteen covariates were selected for the study for determining the risk factors of 
mortality of MDR TB patients and modeling the survival time, a total of 146 patients 
were included in the study out of which 28.7% were died and the rest 71.3% were 
censored. 15 univariable Cox Proportional Hazards regression Model and Weibull 
regression model were developed to assess the relation between the survival status of 
MDR TB patients and the selected variables. Based on the results, the multi-variable Cox 
Proportional Hazards regression Model and Multivariate Weibull regression model of 
duration of survival status was employed to select the most important determinants and 
the research has shown clinical factors are critical in determining survival of patients 
under MDR-TB treatment than socio-demographic factors. 
 The Cox regression analysis showed that Therapeutic delay, initial number of drugs at 
initiation , alcohol use, clinical complication, HIV status of patient and chronic co-
infection were the major factors that affect the survival probability of MDR TB patients 
at Gondar university hospital. In the other hand it was found that factors which had no 
significant impact on the survival of MDR TB patients were sex of the patient, age, 
marital status, educational level, employment status, religion, smoking status, MDR  
category and smear positivity of the patients. Higher hazard of death or lower survival 
rate was noted in patients who started treatment after a month of period diagnosed as 
MDR-TB, patients who take only INH and RIF only, patients who drink alcohol, patients 
who have clinical complications during the treatment period, HIV positive and patients 
who have chronic co-infection. 
 The two parametric regression models: Exponential and Weibull regression models, for 
survival probability of MDR TB patients were compared. The Weibull regression model 
was found to better fit to the data. The major factors that predict the survival probability 
of TB patients were age of the patient, therapeutic delay, number of drugs taken at 
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initiation, alcohol use, any clinical complication, MDR category, HIV co-infection and 
chronic co-infection. Elderly MDR TB patients had higher hazard rate and higher hazard 
of death or lower survival time was noted in patients who started treatment after a month 
of period diagnosed as MDR-TB. However, Patients who took more than INH and RIF at 
initiation, patients who are HIV negative, patients who are previously treated and patients 
who did not take alcohol have higher survival probability (lower hazard rate). MDR`-TB 
patients who have clinical complication and chronic co-infection during treatment have 
lower survival probability (higher hazard rate) relative to MDR-TB patients who have no 
any clinical complication and no chronic co-infection at Gondar university hospital. 
5.2 Recommendation 
Based on the result of the study different factors are identified for the mortality of multidrug 
resistant tuberculosis patients. The following recommendations are made for policy makers, 
clinicians and the public at large. 
 Awareness have to be given for the society on the risk factors of MDR-TB and taking 
care for starting treatment before one month delay after diagnosis to improve their 
survival time. 
 MDR-TB patients who took only INH and RIF have high risk of death. So, patients have 
to come on time to the treatment center and took more than INH and RIF drugs. 
 Elderly MDR-TB patients and previously not treated patients have high hazard of death. 
So that special attention should be given for elderly MDR-TB patients. In addition 
tuberculosis patients should be treated on time to minimize and eliminate the 
development of MDR-TB. 
 This study shows that main predictive factors for the survival time of  MDR-TB patients 
are more clinical variables, so health workers and stakeholders should be cautious when  
patients are alcohol users, have any clinical complications and chronic co-infections, HIV 
positive and they took only INH and RIF at initiation.  
 The government and concerned bodies should work on perception about the problem and 
its risk factors of MDR TB, so that patients should be well informed about the problem 
and early diagnose to give treatment and to stop mortality due to MDR TB. 
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Appendix B 
Table 1B Kaplan-Meier estimates of time to death for MDR TB patients   
Time Total number 
of patients at 
risk 
Total 
number of 
Deaths 
Total 
number of 
Censored  
Survival  Std. 
Error 
[95% Conf. Int.] 
Lower bound   Upper bound 
1      146 3 0 0.9795 0.0117 0.9377 0.9933 
2      143 2 0 0.9658 0.0151 0.9197 0.9856 
3      141 3 2 0.9451 0.0189 0.8931 0.9721 
4      136 2 1 0.9311 0.0210 0.8757 0.9623 
5      133 4 0 0.9031 0.0246 0.8419 0.9414 
6      129 3 0 0.8821 0.0269 0.8172 0.9250 
7      126 1 0 0.8751 0.0275 0.8091 0.9194 
8      125 0 1 0.8751 0.0275 0.8091 0.9194 
9     124 3 2 0.8538 0.0295 0.7845 0.9021 
10   119 1 0 0.8466 0.0301 0.7764 0.8962 
11   118 2 0 0.8322 0.0313 0.7602 0.8843 
12   116 4 0 0.8035 0.0333 0.7282 0.8600 
13   112 2 1 0.7891 0.0342 0.7124 0.8476 
14   109 2 0 0.7746 0.0351 0.6966 0.8350 
15   107 2 2 0.7600 0.0359 0.6807 0.8222 
16   103 2 0 0.7453 0.0367 0.6647 0.8092 
17   101 1 1 0.7379 0.0371 0.6568 0.8027 
18   99 2 1 0.7229 0.0378 0.6407 0.7893 
19   96 2 3 0.7076 0.0385 0.6244 0.7757 
20   91 0 8 0.7076 0.0385 0.6244 0.7757 
21   83 0 10 0.7076 0.0385 0.6244 0.7757 
22   73 1 15 0.6968 0.0394 0.6119 0.7666 
23   57 0 10 0.6968 0.0394 0.6119 0.7666 
24   47 0 41 0.6968 0.0394 0.6119 0.7666 
25   6 0 3 0.6968 0.0394 0.6119 0.7666 
26   3 0 1 0.6968 0.0394 0.6119 0.7666 
27   2 0 1 0.6968 0.0394 0.6119 0.7666 
37   1 0 1 0.6968 0.0394 0.6119 0.7666 
77 
 
 
Table 2B: Results of the univariable proportional hazards Cox regression model  
 
Covariates              
Β 
 
          
SE 
             
Wald 
    
 
df 
 
Sig. 
 
Exp(Β) 
 
LR 
    
 
-2logL 
Sex (Male) -0.051 0.314 0.026 1 0.871 0.950 0.026 401.934 
Age (18-34 years) 
35-54 years 
>=55 years 
 
1.613 
1.706 
 
0.496 
0.517 
12.059 
10.588 
10.890 
2 
1 
1 
0.002 * 
0.001 
0.001 
 
5.017 
5.505 
15.037 384.339 
MRSUS (Single) 
Married 
Separated/Divorced 
Widow/Widowed 
 
0.819 
0.624 
0.771 
 
0.389 
0.558 
0.667 
4.514 
4.435 
1.250 
1.336 
3 
1 
1 
1 
0.211 
0.035 
0.264 
0.248 
 
2.268 
1.866 
2.162 
4.752 396.849 
EDULABL (Illiterate) 
Read and Write 
Secondary 
Tertiary and above 
 
-0.127 
0.125 
-0.305 
 
0.527 
0.472 
0.527 
1.513 
0.058 
0.070 
0.480 
3 
1 
1 
1 
0.679 
0.809 
0.791 
0.488 
 
0.880 
1.133 
0.694 
1.535 400.393 
EMPSUS (Employed) 
Own Business 
Day laborer  
Unemployed 
 
0.355 
0.385 
0.036 
 
 
0.517 
0.671 
0.506 
1.164 
0.475 
0.330 
0.005 
3 
1 
1 
1 
0.762 
0.491 
0.566 
0.943 
 
1.427 
1.470 
1.037 
1.175 400.813 
Religion (Orthodox) 
Muslim 
Protestant 
 
10.024 
10.084 
 
177.105 
177.106 
0.013 
0.003 
0.003 
2 
1 
1 
0.993 
0.995 
0.955 
 
22552.86 
23949.16 
0.732 400.519 
DELAY (>=1 month) -1.047 0.315 11.057 1 0.001* 0.351 12.095 390.662 
NODRUG (INH &RIF only) 1.520 0.364 17.462 1 <0.0001* 4.572 20.985 380.879 
Smokstatus (Smokers) -1.967 0.329 35.689 1 <0.0001* 0.140 48.330 363.796 
Alcoholuse (Yes) -2.206 0.599 13.544 1 0.0002* 0.110 19.974 376.999 
(No Complication) 
Pneumonia 
Pneumothorax 
Hemoptysis 
Cor pulmonal 
  23.625 
18.704 
4.742 
5.586 
11.571 
4 
1 
1 
1 
1 
0.0001* 
0.000 
0.029 
0.018 
0.001 
 28.938 378.356 
1.831 
0.997 
1.223 
1.645 
0.423 
0.458 
0.517 
0.484 
6.239 
2.710 
3.397 
5.181 
Cat (Previously treat ) 1.887 0.313 36.388 1 0.000* 6.601 47.915 368.893 
HIV (Positive) -1.976 0.326 36.675 1 <0.0001* 0.139 49.487 372.953 
Chronic (no chronic)   38.914 3 <0.0001*  54.840 369.589 
Diabetes mellitus  1.085 0.419 6.713 1 0.001 2.958   
Omnibus Tests of Model Coefficients 
-2 Log Likelihood 
401.960 
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Myocardial infraction 2.515 0.486 26.770 1 0.000 12.362   
Asthma 1.987 0.421 22.274 1 0.000 7.292   
SMEAR (Positive) 0.403 0.362 1.239 1 0.266 1.497 1.256 400.810. 
 The reference categories are those indicated in brackets     * the covariate is significant 
at the 0.05 level. 
Table 3B: Result of the multivariable proportional hazard regression model containing the variables 
significant in the univariabe proportional hazard model. 
Omnibus Tests of Model Coefficients 
-2 Log Likelihood 
285.062 
 
 Covariates  B SE Wald X
2
 df Sig. Exp(B) 
DELAY(>=1 month) -1.098 0.456 5.809 1 0.016 0.333 
NODRUG (INH &RIF only) -1.264 0.423 8.947 1 0.003 0.282 
Smokstatus (smokers) -0.685 0.392 3.043 1 0.081 0.505 
Alcoholuse (Yes) -1.462 0.630 5.383 1 0.020 0.232 
(No Complication) 
Pneumonia 
Pneumothorax 
Hemoptysis 
Cor pulmonal 
  10.384 
3.427 
0.211 
0.596 
8.391 
4 
1 
1 
1 
1 
0.034 
0.064 
0.646 
0.440 
0.004 
 
0.955 
-0.254 
0.463 
1.641 
0.516 
0.554 
0.599 
0.567 
2.598 
0.775 
1.588 
5.161 
HIV (Positive) -1.602 0.392 16.726 1 0.000 0.201 
Chronic (no chronic) 
Diabetes mellitus 
Myocardial infraction 
Asthma 
  18.543 
3.470 
15.125 
8.204 
3 
1 
1 
1 
0.000 
0.062 
0.000 
0.004 
 
1.015 
2.309 
1.434 
0.545 
0.594 
0.501 
2.759 
10.062 
4.196 
       The reference categories are those indicated in brackets. 
Table 4B: Result of Wald statistic P-values when possible interactions terms included in reduced model 
one at a time 
Interaction between covariates DF Wald P-Value 
Therapeutic delay Number of Drugs  1 0.605 0.437 
Alcohol use 1 0.337 0.561 
Clinical complication 4 0.995 0.911 
HIV Co-infection 1 0.291 0.590 
79 
 
Chronic disease 3 0.640 0.887 
Number of Drugs Alcohol use 1 0.489 0.484 
Clinical complication 4 1.372 0.849 
HIV Co-infection 1 0.589 0.443 
Chronic disease 3 0.824 0.844 
Alcohol use Clinical complication 4 0.907 0.924 
HIV Co-infection 1 0.041 0.839 
Chronic disease 3 0.272 0.965 
Clinical complication HIV Co-infection 4 5.722 0.221 
Chronic disease 12 8.270 0.764 
HIV Co-infection Chronic disease 3 1.699 0.637 
 
Table 5B: Result of the Exponential regression model with corresponding AIC and BIC values 
Exponential regression -- log relative-hazard form  
No. of subjects =          146                      Number of obs   =       146    No. of failures =           42 
Time at risk    =         2655                          LR chi
2
 (15)     =    110.04 
Log likelihood =   -77.325422                     Prob > chi2     =    0.0000       
_t Coef. Std. Err. Z P>|z| [95% Conf. Interval] 
Lower Upper  
Sex 0.0452588 0.4166544 0.12 0.908 -0.7684673 0.8647879 
Age 0.6768404 0.2812544 2.41 0.016 0.1255919 1.228089 
MRSUS -0.2481689 0.2461084 -1.01 0.313 -0.7305325 0.2341948 
EDULABL -0.2191629 0.220709 -0.99 0.321 -0.6517445 0.2134188 
EMPSUS -0.0376534 0.1360608 -0.28 0.782 -0.3043277 0.2290208 
Religion -0.2032551 0.6883346 -0.30 0.768 -1.552366 1.145856 
DELAY -1.060755 0.402847 -2.63 0.008 -1.85032 -0.2711891 
NODRUG -0.9018496 0.3901495 -2.31 0.021 -1.666529 -0.1371706 
Smokstatus -0.724259 0.3992386 -1.81 0.070 -1.506752 0.0582344 
Alcoholuse -1.444988 0.6567524 -2.20 0.028 -2.732199 -0.1577769 
Clnccomplicn 0.2377893 0.1342939  1.77 0.077 -0.025422 0.5010006 
MDRCAT 0.5181894 0.417035  1.24 0.214 -0.2991842 1.335563 
HIV -1.131205 0.438505  -2.58 0.010 -1.990659 -0.2717514 
CHRONIC 0.471997 0.1572761  3.00 0.003 0.1637415 0.7802524 
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SMEAR 0.3752426 0.537844  0.70 0.485 -0.6789123 1.429398 
_cons -2.563492 0.9821159 -2.61 0.009 -4.488404 -0.638580 
----------------------------------------------------------------------------- 
       Model               Obs      ll(null)     ll(model)     df        AIC            BIC 
-------------                 --------------------------------------------------------------- 
           .                    146   -132.3478    -77.32542     16      186.6508    234.3886 
----------------------------------------------------------------------------------------------- 
Note:  N=Obs used in calculating BIC; see [R] BIC note 
Table 6B: Result of the Weibull regression model with corresponding AIC and BIC values 
Weibull regression -- log relative-hazard form  
No. of subjects =          146                     Number of obs   =       146    No. of failures = 42 
Time at risk    =         2655                         LR chi
2 
(15)     =    119.39 
Log likelihood =   -72.650423                     Prob > chi2     =    0.0000 
  _t Coef. Std. Err. z P>|z| [95% Conf. Interval] 
Lower  Upper  
 Sex -0.032851 0.4370747 -0.08 0.940 -0.8895017 0.8237998 
Age 0.8000984 0.2970161 2.69 0.007 0.2179576 1.382239 
MRSUS -0.294247 0.2521145 -1.17 0.243 -0.7883824 0.1998883 
EDULABL -0.2265574 0.2338126 -0.97 0.333 -0.6848217 0.2317068 
EMPSUS -0.0144881 0.1405208 -0.10 0.918 -0.2899038 0.2609276 
Religion -0.3911726 0.7305728 -0.54 0.592 -1.823069 1.040724 
DELAY -1.225845 0.4204272 -2.92 0.004 -2.049867 -0.4018227 
 NODRUG -1.007244 0.3955844 -2.55 0.011 -1.782576 -0.2319133 
Smokstatus -0.7865751 0.4104426 -1.92 0.055 -1.591028 0.0178775 
 Alcoholuse -1.395812 0.6557236 -2.13 0.033 -2.681006 -.1106173 
Clnccomplicn 0.2576345 0.1382996 1.86 0.062 -0.0134278 0.5286968 
 MDRCAT 0.7362727 0.4412978 1.67 0.095 -0.1286552 1.601201 
 HIV -1.256401 0.4674504 -2.69 0.007 -2.172587 -0.3402154 
CHRONIC 0.5414255 0.1612987 3.36 0.001 0.225286 0.8575651 
SMEAR 0.2253239 0.5596175 0.40 0.687 -0.8715061 1.322154 
 _cons -4.126206 1.174263 -3.51 0.000 -6.427719 -1.824693 
/ln_p 0.4502536 0.1350796 3.33 0.001 0.1855025 0.7150048 
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 P 1.56871 0.2119007     1.203823 2.044196 
1/p 0.6374664 0.0861087     0.4891898 0.830686 
----------------------------------------------------------------------------- 
       Model                Obs      ll(null)     ll(model)     df          AIC         BIC 
-------------                 --------------------------------------------------------------- 
           .                      146     -132.345   -72.65042     17      179.3008    230.0222 
-------------------------------------------------------------------------------------------------- 
               Note:  N= Obs used in calculating BIC; see [R] BIC note 
Table 7B: results of the step wise variable selection of weibull regression analysis.  
p = 0.0826 >= 0.0500 removing Smokstatus 
Weibull regression -- log relative-hazard form  
No. of subjects =          146 Number of obs   = 146 
No. of failures =           42 
Time at risk    =         2655 
                                                        LR chi
2 
(8)      = 113.92 
Log likelihood =   -75.385077         Prob > chi2     = 0.0000 
 
_t                Coef. Std. Err.       z P>z      [95% Conf. Interval] 
Lower  upper 
Age 0.748324 0.2422695      3.09 0.002      0.2734844 1.223164 
DELAY -1.219319 0.3421733     -3.56  0.000      -1.889967 -0.548672 
NODRUG -1.111739 0.3778737     -2.94 0.003     -1.852357 -0.3711196 
CHRONIC 0.5587804 0.1339457      4.17 0.000      0.2962517 0.8213091 
Alcoholuse -1.46689 0.6164538     -2.38 0.017     -2.675117 -0.2586624 
Clnccomplicn 0.3121017 0.1206824 2.59 0.010      0.0755685 0.5486349 
MDRCAT 0.9551259 0.3541405      2.70 0.007     0.2610233 1.649228 
HIV -0.9944914 0.3669531     -2.71 0.007     -1.713706 -0.2752765 
_cons             -5.265299 0.8774824 -6.00 0.000     -6.985133 -3.545465 
ln_p              0.4247582 0.1320765      3.22 0.001      0.1658931 0.6836233 
p    1.529221 0.201974   1.180447 1.981043 
1/p                       0.6539279 0.0863685   0.5047847 0.8471368 
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Appendix C 
Figures 1C: Plots of Kaplan-Meier survivor functions, for different covariates 
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Figure 5C: Plots of the Scaled Schoenfeld residuals and their lowess smooth obtained from the final 
model for the covariate any clinical complication of the patient. 
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Appendix D: STATA and SAS codes 
 
STATA codes  
 
global time  TIME 
global event  STATUS 
 
stset TIME, failure(STATUS) 
stdescribe 
stsum 
 
label var  Sex "gender of the patient" 
label define Sex 0"Male" 1"Female"    
label value Sex Sex 
 
           gen Age=. 
           replace Age=0 if Age>18 & Age<=34 
           replace Age=1 if Age>34 & Age<=54 
           replace Age =2 if Age>54  
           label var Age "Age of the patient" 
           label define Age 0"18-34 years " 1"34-54 years " 2"55 & above"  
           label value Age Age 
           tab Age 
 
label var MRSUS "marital status of the patient" 
label define MRSUS 0"Single" 1"Married" 2"Separated/Divorced" 
3"Widow/Widowed"     
label value MRSUS MRSUS  
 
label var EDULABL "Educational label of the patient " 
label define EDULABL 0"Illiterate" 1"Read and Write" 2"Secondary" 
3"Teritiary and above"   
label value EDULABL EDULABL  
 
label var EMPSUS "Employment status of the patient " 
label define EMPSUS 0"Employed" 1"Own Business" 2"day laborer" 
3"Unemployed"  
label value EMPSUS EMPSUS 
 
label var Religion " Religion of the patient " 
label define Religion 0"Orthodox" 1"Muslim" 2"Protestant" 3"Others"  
label value Religion Religion 
 
label var DELAY "Therapeutic Delay" 
label define DELAY 0">= 1 month" 1"< 1 month"    
label value DELAY DELAY 
 
label var NODRUG "Number of drugs at initiation" 
label define NODRUG 0"INH and RIF only" 1"more than INH and RIF"    
label value NODRUG NODRUG 
 
label var Smokstatus " Smoking status" 
label define Smokstatus 0"Yes 1"No"    
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label Smokstatus Smokstatus 
 
 
label var Alcoholuse " Alcohol use" 
label define Alcoholuse 0"Yes 1"No"    
label Alcoholuse Alcoholuse 
 
label var Clnccomplicn "any clinical complication" 
label define Clnccomplicn 0"No complication" 1"Pneumonia" 2"Pneumothorax" 
3"Hemoptysis" 4"Cor pulmonal"    
label value Clnccomplicn  Clnccomplicn  
 
label var MDRCAT " MDR Category" 
label define MDRCAT 0"Previously treated"  1"Previously not Treated"    
label MDRCAT MDRCAT 
 
 
label var HIV " HIV co-infection" 
label define HIV 0"Positive"  1"Negative"    
label HIV HIV 
 
label var CHRONIC "any clinical complication" 
label define CHRONIC 0"No chronic disease" 1"Diabetes mellitus" 
2"Myocardial infraction " 3"Asthma"     
label value CHRONIC CHRONIC 
 
label var SMEAR " Smear positivity" 
label define SMEAR 0"Positive"  1"Negative"    
label SMEAR SMEAR 
 
streg Sex Age MRSUS EDULABL EMPSUS Religion DELAY NODRUG Smokstatus 
Alcoholuse Clnccomplicn MDRCAT HIV CHRONIC SMEAR ,nohr dist(exponential) 
 
streg i.Age DELAY  NODRUG    Alcoholuse  i.Clnccomplicn  MDRCAT  HIV i.CHRONIC, nohr  
dist(weibull) 
 
streg Sex Age MRSUS EDULABL EMPSUS Religion DELAY NODRUG Smokstatus 
Alcoholuse Clnccomplicn MDRCAT HIV CHRONIC SMEAR ,nohr dist(weibull) 
 
xi: stepwise,pr(0.05): streg  Age DELAY  NODRUG  Smokstatus  Alcoholuse  Clnccomplicn  
MDRCAT  HIV CHRONIC,nohr dist(weibull) 
 
streg Age DELAY  NODRUG    Alcoholuse  Clnccomplicn  MDRCAT  HIV CHRONIC, 
nohr  dist(weibull) 
scalar m1 = e(ll) 
estimates store m1 
streg  ,nohr dist(weibull) 
scalar m2 = e(ll) 
estimates store m2 
lrtest m2 m1 
 
estat ic: stata command for computing AIC and BIC after a model have been                   
already fitted 
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SAS codes 
data MDR;                                                                                                                                
input DELAY  NODRUG  Smokstatus  Alcoholuse  Clnccomplicn  HIV   CHRONIC  TIME  
STATUS;                                                  
datalines; 
;                                                                                                                                        
proc print;                                                                                                                              
run;                                                                                                                                     
proc phreg data=MDR;                                                                                                                     
model TIME*STATUS(0)= DELAY  NODRUG  Smokstatus  Alcoholuse  Clnccomplicn  HIV   
CHRONIC;                                                
run;                                                                                                                                     
proc phreg data=MDR;                                                                                                                     
title "test of proportionality assumption";                                                                                              
model TIME*STATUS(0)= DELAY  NODRUG  Smokstatus  Alcoholuse  Clnccomplicn  HIV   
CHRONIC DELAYT NODRUGT SmokstatusT AlcoholuseT          
ClnccomplicnT HIVT CHRONICT;                                                                                                            
DELAYT = DELAY*log(TIME);                                                                                                                
NODRUGT = NODRUG*log(TIME);                                                                                                              
SmokstatusT = Smokstatus*log(TIME);                                                                                                      
AlcoholuseT = Alcoholuse*log(TIME);                                                                                                      
ClnccomplicnT = Clnccomplicn*log(TIME);                                                                                                  
HIVT = HIV*log(TIME);                                                                                                                    
CHRONICT =  CHRONIC*log(TIME);                                                                                                           
test_proportionality: test DELAY, NODRUG, Smokstatus, Alcoholuse, Clnccomplicn, HIV, 
CHRONIC;                                            
run; 
data MDR;                                                                                                                                                                                                                                                        
input Sex Age  MRSUS  EDULABL  EMPSUS  Religion  DELAY  NODRUG  Smokstatus  Alcoholuse  
Clnccomplicn  MDRCAT  HIV CHRONIC SMEAR  TIME  STATUS;                                                                                                                   
datalines; 
;                                                                                                                                                                                                                                                               
proc print;                                                                                                                                                                                                                                                      
run;                                                                                                                                                                                                                                                             
proc lifereg data=MDR;                                                                                                                                                                                                                                           
model TIME*STATUS(0) =  Age  DELAY  NODRUG  Smokstatus  Alcoholuse  Clnccomplicn  
MDRCAT  HIV CHRONIC  / distribution=weibull;                                                                                         
run; 
proc lifereg data=MDR noprint;                                                                                                                                                                                                                                   
model TIME*STATUS(0) = Sex Age  MRSUS  EDULABL  EMPSUS  Religion  DELAY  NODRUG  
Smokstatus  Alcoholuse  Clnccomplicn  MDRCAT  HIV CHRONIC SMEAR / 
distribution=exponential;                                                                                     
output out= exp cdf=f;                                                                                                                                                                                                                                           
run;                                                                                                                                                                                                                                                             
data exp1;                                                                                                                                                                                                                                                       
  set exp;                                                                                                                                                                                                                                                       
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  cox = -log( 1-f );                                                                                                                                                                                                                                             
run;                                                                                                                                                                                                                                                             
proc lifetest data=exp1 outsurv=surv_exp noprint;                                                                                                                                                                                                                
TIME cox*STATUS(0);                                                                                                                                                                                                                                              
run;                                                                                                                                                                                                                                                             
data surv_exp;                                                                                                                                                                                                                                                   
  set surv_exp;                                                                                                                                                                                                                                                  
  ls = -log(survival);                                                                                                                                                                                                                                           
run;                                                                                                                                                                                                                                                             
goptions reset=all;                                                                                                                                                                                                                                              
axis1 order=(0 to 5 by 1) minor=none label=('Exponential Reg Model Cum Hazard');                                                                                                                                                                                 
axis2 order=(0 to 5 by 1) minor=none label=( a=90 'Kaplan-Meier Cum Hazard');                                                                                                                                                                                    
symbol1 i=l1p  c= blue v=dot h=.4;                                                                                                                                                                                                                               
symbol2 i = join c = red l = 3;                                                                                                                                                                                                                                  
proc gplot data=surv_exp;                                                                                                                                                                                                                                        
  plot (ls cox)*cox / overlay haxis=axis1 vaxis= axis2;                                                                                                                                                                                                          
run;                                                                                                                                                                                                                                                             
quit;   
proc lifereg data=MDR noprint;                                                                                                                                                                                                                                   
model TIME*STATUS(0) = Sex Age  MRSUS  EDULABL  EMPSUS  Religion  DELAY  NODRUG  
Smokstatus  Alcoholuse  Clnccomplicn  MDRCAT  HIV CHRONIC SMEAR / 
distribution=weibull;                                                                                         
output out= weibull cdf=f;                                                                                                                                                                                                                                       
run;                                                                                                                                                                                                                                                             
data weibull1;                                                                                                                                                                                                                                                   
set weibull;                                                                                                                                                                                                                                                     
cox = -log( 1-f );                                                                                                                                                                                                                                               
run;                                                                                                                                                                                                                                                             
proc lifetest data=weibull1 outsurv=surv_wei noprint;                                                                                                                                                                                                            
 TIME cox*STATUS(0);                                                                                                                                                                                                                                             
run;                                                                                                                                                                                                                                                             
data surv_wei;                                                                                                                                                                                                                                                   
  set surv_wei;                                                                                                                                                                                                                                                  
  ls = -log(survival);                                                                                                                                                                                                                                           
run;                                                                                                                                                                                                                                                             
goptions reset=all;                                                                                                                                                                                                                                              
axis1 order=(0 to 5 by 1) minor=none label=('Weibull Reg Model Cum Hazard');                                                                                                                                                                                     
axis2 order=(0 to 5 by 1) minor=none label=( a=90 'Kaplan-Meier Cum Hazard');                                                                                                                                                                                    
symbol1 i=l1p  c= blue v=dot h=.4;                                                                                                                                                                                                                               
symbol2 i = join c = red l = 3;                                                                                                                                                                                                                                  
proc gplot data=surv_wei;                                                                                                                                                                                                                                        
  plot (ls cox)*cox / overlay haxis=axis1 vaxis= axis2;                                                                                                                                                                                                          
run;                                                                                                                                                                                                                                                             
quit; 
